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Doxorubicin (DOX) and Mitomycin C (MC) are commonly used 
antineoplastic drugs in clinics. They show high effectiveness in tumor 
chemotherapy against various human soft or solid tumors. To exert their 
cytotoxicity, D O X and M C require biotransformation of parent drugs to highly 
reactive quinone intermediates by endogenous reductases or dehydrogenases. 
These activated intermediates intercalate D N A of the tumor cells and thus inhibit 
their proliferation leading to cell cycle arrest and death. However, under aerobic 
condition, these quinone intermediates would induce the production of free 
radicals, such as superoxides, hydroxyl radicals, etc., and impose an oxidative 
stress to the host. These highly reactive free radicals from D O X and M C drug 
action destroy nearby normal tissues by D N A oxidation, protein oxidation and 
lipid peroxidation. This damage causes the predominant adverse side effects of 
D O X and M C to patients in cancer chemotherapy. These side effects are dose-
dependent and cumulative, thus limit the amount of D O X and M C that can be 
V-
‘ received by the patients. 
Normal tissues possess endogenous defence systems that maintain the 
balance of oxidants and antioxidants. This is achieved by enzymes, such as 
superoxide dismutase, catalase, glutathione reductase/ peroxidase, and by small 
molecules, such as vitamin C, E or glutathione (GSH), etc. However, some 
organs, i.e. heart, possesses little or no such defence system that they become the 
most susceptible to the free radical attack from the adverse side effects of D O X 
• • 
11 
and M C . W e tested whether concomitant treatment of antioxidants with D O X 
and M C can eliminate the free radical generation adverse side effect generated 
by D O X or M C W e have studied the cardioprotective effects of (+)-Catechin and 
Flavone (both were flavonoids) and n-propyl gallate (a garlic acid). 
In human normal endothelial cell line (ECV304), these two antioxidants 
showed protective effects to the cytotoxicity of D O X and M C under aerobic 
condition. In human heptoma cell line (HepG2), these two antioxidants did not 
protect the tumor cells from D O X or M C treatment but showed enhanced anti-
proliferative effect. Moreover, n-propyl gallate and flavone induced the 
expression of Mn-SOD m R N A in ECV304 cells treated with D O X or M C . This 
effect could not be found in HepG2 cells under the same treatment. 
In Ehrlich ascites tumor (EAT)-bearing mice, w e found that repetitive 
treatment of (+)-Catechin and n-propyl gallate did not affect the cytotoxicity of 
D O X or M C on EAT cells. The n-propyl gallate could protect the hearts of EAT-
bearing mice from damage caused by D O X . This effect was observed in the 
‘V 
histological preparation of heart sections. The disruption of myofibrils in 
myocytes was reduced by concomitant treatment of n-propyl gallate. O n the 
other hand, in a Langendorff perfused isolated rat heart model, (+)-Catechin was 
found to protect isolated rat hearts from D O X or M C damages by recovering the 
contraction force, flow rate and heart beat frequency. 
In addition, w e have used exogenous ATP to suppress the growth of 
hepatoma (HepG2). The growth inhibition was found to be high in tumor cells 
• •參 
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but very low in normal cells (ECV304). W e have used exogenous A T P to 
suppress the growth of E A T cells in mice and thus less D O X was needed to 
eliminate the E A T cells compared to using D O X only. 
By different means, w e have showed that the free radicals-mediated side 
effect of D O X or M C could be reduced by concomitant treatment with natural 






















































A T P Adenosine 5'-triphosphate 
B H T Butylated hydroxytoluene 
BSO L-buthionine sulfoximine 
C A T (+)-Catechin 
Cu Cupper 
D E M Dimethyl maleate 
D N A Deoxyribonucleic acid 
D O X Doxorubicin 
E A T Ehrlich ascites tumor 
E C Extracellula 
ECV304 H u m a n umbrilical cord endothelial cell line 
FCS Fetal Calf Serum 
G S H Glutathione (reduced) 
GSSG Glutathione (oxidized) 





M C Mitomycin C 
MCF-7 H u m a n breast cancer cell line 
M D A Malonedialdehyde 
M n Manganese 
m R N A messenger R N A 
M T T Methylthiazol tetrazolium 
PBS Phosphate buffer saline 
PG N-Propyl gallate 
R N A Ribonucleic acid 
RPMI1640 Roswell Park Memorial Institude tissue culture 
medium 1640 
SDS Sodium dodecylsulfate 
S O D Superoxide dismutase 
TBA Thiobarbituric acid 
T C A Trichloroacetic acid 
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CHAPTER ONE INTRODUCTION 
1. Free radical and free radical-mediated antitumor drugs 
A free radical is any molecule containing a single, unpaired electron, 
such as superoxide radical, hydroxyl radical, etc., which can be found in 
organisms, like human. It is well-known that under normal biological 
conditions, free radicals are formed as by-products of many biochemical 
reactions. These free radical generating reactions can be catalyzed by enzymes 
and ions of transition metals, such as superoxide dismutase and iron ions. 
Superoxides are generated from the bactericidal action of phagocytes. 
W h e n neutrophils encounter and kill microorganisms, they will consume 
oxygen, resulting in hydrogen peroxide production (Babior, 1978). 
Mitochondria produce superoxide anions at two sites in the electron 
transport chain. The first site is the ubiquinone to cytochrome ci step, which 
H_-
^ passes through the intermediate ubisemiquinone (Turrens et al., 1985). 
Ubisemiquinone is capable of reducing oxygen to superoxide, which 
dismutates spontaneously to form hydrogen peroxide and is catalyzed by 
NADH-dehydrogenase (Turrens and Boveris, 1980). 
Xanthine oxidase exists in vivo primarily as a dehydrogenase form, 
which uses N A D + as an electron acceptor during the oxidation of xanthine 
and hypoxanthine (Battelli et al., 1972). In tissues containing abundant 
xanthine dehydrogenase, this enzyme becomes an important source of 
superoxide upon tissue reoxygenation after ischemia or after extreme 
1 
Introduction 
M ^ M a B M B a ^ ^ ^ B ^ B S a a S B S B a S ^ ^ ^ ^ B ^ S B B B S B B B ^ ^ S S a B S S S S a ^ S S B S S S S B ^ B B S S S S B B S B ^ B B S B S B B B S B S S ^ ^ B B S ： ^ ^ 
hypotension (Saugstad et al., 1976). About 10% of any tissue's xanthine 
dehydrogenase exists as an oxygen-utilizing superoxide-producing xanthine 
oxidase (McCord, 1985). 
Besides the above three major sources of free radicals, there are several 
other sources suggested as well. Arachidonic acid metabolism via 
prostaglandin synthase and lipoxygenase appears to generate superoxide 
radicals (Kukreja et al., 1986). The auto-oxidation of catecholamines, which 
generates superoxide (Cohen, 1984), has been proposed to cause myocardial 
damage during ischemia and reperfusion (Singal et al, 1982). Hemoproteins 
such as myoglobin may participate in active oxygen-dependent free radical 
injury (Arduini et al., 1990). 
Some of the known free radical-mediated antitumor drugs included 
Mitoxantrone, Ametantrone, Carbazilquinone, Diaziquone, Streptonigrin, 
Actinomycin D, Menadione, Daunorubicin, Aclacinomycin A, etc. In this 
research, two of free radicals-mediated antitumor drugs. Doxorubicin (DOX) 
V 
. and Mitomycin C (MC) were studied. 
2. Mitomycin C (MC) 
2.1 Drug actions of MC 
Mitomycin C (MC) is one of -the commonly used clinical antitumor 
drugs. It was firstly isolated from the fermentation of broth of Streptomyces 
caespitosus and introduced into clinical trials in which its anticancer activity 
was confirmed in humans. It exhibits a broad spectrum of antitumor activity 
2 
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in chemotherapy of cancers of breast, lung, prostate, colorectal and superficial 
bladder. 
The chemical structure of M C consists of a mitosane and quinone 
moiety (Figure 1) which promotes facile enzymatic reduction, good aqueous 
solubility and low lipophilicity leading to enhanced antitumor activity 
(Powis, 1989). To exert its drug action in tumors, M C requires enzymatic 
reduction, preferentially under anaerobic conditions, resulting in crosslinking 
of D N A . Large tumor masses are known to contain markedly hypoxic 
populations of cells that are extremely resistant to drugs and to ionizing 
radiation therapy. It was reported that M C was more cytotoxic to hypoxic 
cells than to normoxic cells (Kennedy et al., 1980). These studies have 
documented an enhanced rate and efficiency for reductive metabolic 
activation of M C under hypoxic conditions. This mechanism was termed 
anaerobic bioreductive alkylation (Moore, 1977). The enzymes which are 
capable of reducing M C include NAD(P)H:oxidoreductase, N A D P H -
�,-
. cytochrome P450 reductase, xanthine:oxidase oxygen oxidoreductase and 
xanthine dehydrogenase, etc. It was shown that many human tumors, such as 
cancers of liver, colon, breast and non-small cell lung, were rich in 
NAD(P)H:oxidoreductase, making these tumors more susceptible to M C 
(Nishiyama et al., 1993). The first stage in activation of M C is quinone 
reduction, either through an one electron pathway producing a semiquinone 
free radical intermediate or a two electron pathway producing a 
3 
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Figure 1.1 Molecular structure of Mitomycin C (MC). 
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hydroquinone intermediate (Figure 1.2). These intermediates can act as a 
monofunctional alkylating agent and bind to D N A , R N A , and protein, or it 
can act as a bifunctional alkylating agent and crosslink complementary 
strands of D N A , or crosslink D N A with proteins; thus inhibit cell growth in 
tumors. 
2.2 Adverse side effects of MC 
In normal tissues which were well-oxygenated, the quinone 
intermediates of M C produced after enzymatic reduction react with oxygen 
by entering a redox cycle and catalyz the formation of superoxide, with a 
subsequent metal-dependent generation of hydrogen peroxides and hydroxyl 
radicals (Doroshow, 1981; Hamana et al, 1985). These free radicals are called 
reactive oxygen species (ROS). The intranuclear or extracellular hydroxyl 
radicals formed can cause oxidative destruction of nearby or distant 
V' 
. biomolecules, such as D N A , enzymes, membrane phospholipids and 
receptors, etc. These free radicals can cause irreversible damages in normal 
tissues, e.g. heart, and are one of the causes of the adverse side effects of M C 
in clinical studies. A summary of drug actions of M C in both tumor and 
normal tissues is shown in Figure 1.5. 
The level of enzymatic antioxidants in the hearts is very low 
(Doroshow et al., 1980). It shows no or little defense system against free 
radical damages. Superoxide and hydrogen peroxide formation in rat heart 
are enhanced by M C (Doroshow, 1981). Hydroxyl radicals are formed by 
5 
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M C in cardiac microsomes and perfused rat hearts and cause acute 
arrhythmia and cardiac standstill (Ploiti et aL, 1989). It was also found that 
tissues specific disruption of cellular bioenergetics, i.e. mice heart 
mitochondria A T P synthesis, was found following M C exposure resulting in a 
decrease of tissue A T P levels (Pritsos and Briggs, 1996). 
In clinical studies, this cardiotoxicity is also observed in patients w h o 
had received M C treatments, especially when combined with or given 
following Doxorubicin (DOX). The cardiotoxicity in patients is often 
expressed by left ventricular failure (Verweij et aL, 1987). Cardiac failure is 
observed, and this effect is cumulative and dose-dependent (Verweij et al., 
1988). Others adverse side effects include hemolytic uremic syndrome, bone 
marrow suppression, thrombocytopenia, etc. 
Although M C is very effective in chemotherapy of cancers, its clinical 
applications are limited by its severe adverse side effects which are 
cumulative and dose-dependent in patients. In order to retain its usage and 
V 
. dosage, various strategies are being developed to minimize its adverse side 
effects and at the same time, to enhance its antitumor activity. 
3. Doxorubicin (DOX) 
3.1 Drug actions of DOX • 
Doxorubicin (DOX) is an anthracycline antibiotic originally isolated 
from the fungus, Streptomyces peucetius (Arcamone et al., 1972). It is a 
7 
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chemotherapeutic drug with strong activity against a wide range of human 
malignant neoplasm including acute leukemia, non-Hodgkin lymphomas, 
breast cancer, Hodgkin's disease and sarcomas. The chemical structure of 
D O X consists of water-insoluble quinone methide moiety and a water-soluble 
reducing daunosamine sugar (Figure 1.3). Like Mitomycin C, so as to exert its 
antitumor effects, D O X requires enzymatic reductions (Figure 1.4) by 
common reductive enzymes, such as N A D P H cytochrome P450 reductase, 
N A D H dehydrogenase, etc., to form quinone methide intermediates. These 
reactive quinones can inhibit mitochondrial oxidative phosphorylation 
(Muhammed et al, 1982), D N A polymerases, R N A polymerases and D N A 
repair enzymes (Bachur et al., 1992) and modulate membranes (Tritton, 1991). 
Also D O X can inhibit synthesis of metallothioneins, cysteine-rich proteins that 
interact with many electrophilic toxins (Webber et aL, 1988) and inhibit 
topoisomerase I (topo I ) so as to insert transient breaks into one strand of 
duplex D N A (Foglesong et aL, 1992) and produce free radicals (Bachur et al., 
V 
. 1992). These then impair the replication and growth of tumors. 
3.2 Adverse side effects of DOX 
In normal tissues, which are well-oxygenated, the quinone derivatives 
of D O X , via enzymatic reduction, will reduce oxygen by entering the 'redox-
cycling'. Numerous superoxide radicals are formed. Highly reactive hydroxyl 
radicals are then produced from these superoxide radicals, catalyzed by ions 
of transition metals, such as iron ions. The hydroxyl radicals are believed to 
be the main cause of oxidative destruction of nearby and distant 
8 
Introduction 
H H M H ^ ^ ^ ^ B B B B I H B 8 B H B a B B H a B B B B 8 B a a B B a a B B a B a a B a B ^ ^ ^ ^ B ^ ^ ^ H ^ ^ ^ ^ K a B B a B S ^ ^ a B B B ^ H B a B B H a H B B B I B B B H a ^ ^ H B B a B ^ ^ B B B I B ^ ^ ^ B H H 
0 OH 0 
r^^^^^^^V"V^KOH 
\ z O H 
^ v ^ ^ " S < ^ " N ^ ^ ^ ^ 
I 
OMe 0 OH 6 
0 ^ 
x ^ / N H 
H 3 C ^ ^ ^ 
N H 2 
Doxorubicin (DOX) 




•uopDB Snjp (xoa) upiqnioxoa }o uisjucipdui 
a^) ui sa;Fipduii9)ui SupB|X>[|F pvre stBDipci aajj y i a:mSij 
sax3|duio9 
e|n3a|ouioj9eui-6njQ 
su!3)Ojd VN« VNQ 
je6nS\ 、 
0 HO 0 9|AIO 
r^"^^r<^^^^^V:^^^^v;;=^ 
HoJ T T T y 
d o o ^ ^ ^ ^ / ^ V ^ V ^ ^ ^ 
HG 0 HdOVN 
' 、 厂 � 广 
uopBppcoiad pidn \ \ / 
^ I *asB)^ np9j 
\ 八 "i)SW auion|[3o;X9.3.a 
\ / \ 'samXzud aAi43npa^ [ \ 
一 | \ y V . \ 
( o*8'HO '^O^Vi)''^0^'^ / \ ^ 
/
jB6nSv^ Z +dOVN 
VNQ 0 H 0 0 0|AIO 
r^ ^^ N^^ ^^ ^^ ^^ ^^ ^^ r^"^  
Sup|Dni VNQ H0, I I 
y o o ^ ^ ^ ^ ^ ^ l ^ ^ ^ ^ | ^ ^ 








M H ^ H B H B a e n ^ B = ^ B s : ^ s = = a a s s = s s B s s a s = s s = s s s s : s ^ ^ = = s = s s = s s s a s a s B a ^ = = : = ^ S B B S s s ^ = B = B = = : ^ B S s s s ^ s a = ^ = s = s s s = s ^ B 
biomolecules, such as D N A , enzymes, membrane phospholipids, receptors, 
etc. (Sinha and Mimnaugh, 1990). A summary of D O X drug actions in both 
tumor and normal tissues is shown in Figure 1.5. 
The use of D O X in chemotherapy of cancer is largely limited by its 
profound side effects causing cardiotoxicity, i.e. cardiomyopathy leading to 
congestive heart failure (Pawan et al, 1997). Most of the studies support the 
view that the main cause of DOX-induced cardiotoxicity is the oxidative stress 
evidenced by an increase in free radicals and lipid peroxidation as well as a 
decrease in antioxidants and sulfhydryl groups in cardiocytes of the host 
(Singal et al, 1995). The biochemical events that might play a role in the 
pathogenesis of cardiotoxicity include abnormalities in mitochondria function 
(Gosalvez et aL, 1979), lysosomal changes (Singal et al, 1985); imbalance in 
myocardial electrolytes (Olson et al, 1974) and formation of free radicals, lipid 
peroxidation and depletion of non-protein tissue sulfhydryl groups (Singal et 
al, 1987). 、 
In patients, the cardiomyopathy of D O X can be categorized as acute 
and chronic. Acute effects include tachycardia, hypotension and various 
electrocardiogram changes (van Acker et al, 1996). Chronic effects are 
irreversible cardiomyopathic change& leading to congestive heart failure with 
grave prognosis. Typical clinical characteristics of advanced D O X 
cardiomyopathy are a serious decrease in blood pressure and markedly 





with subsequent failure (Lefrak et al, 1973). Moreover, the cardiomyopathy is 
also characterized by a specific ultrastructural pathology. Cytoplasmic 
vacuolization due to dilation of the sarcotubules and loss of myofibrils are the 
main features in cardiac biopsies from patients treated with D O X (Buja et al., 
1973). The cardiotoxicity of D O X is found to be dose-dependent and 
cumulative as well. 
As a result, the use of D O X is restricted even though it shows great 
efficacy in chemotherapy in variety of soft and solid human malignancies. 
Therefore, there is still a need to find ways to avoid or minimize the 
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In normal tissues, there are various kinds of endogenous defense 
systems which protect the host against the free radicals stress produced from 
normal physiological conditions or metabolism of xenobiotics. These defense 
systems consist of small molecules and a cascade of cytoplasmic or 
membrane-bound enzyme systems which act at either hydrophobic or 
hydrophilic environments. The small molecules include vitamin A, E and C, 
glutathione, urate, etc. Some of the components of the enzyme cascade are 
catalase, different isoforms of superoxide dismutase (SOD), i.e. Mn-SOD, 
Cu/Zn-SOD and extracellular SOD, glutathione-related enzymes such as 
glutathione reductase, peroxidase, transferase, etc. 
According to the drug actions of both M C and D O X in normal well-
oxygenated tissues, free radicals, such as superoxides, hydroxyl radicals, etc., 
V 
are formed during the redox cycling of quinone derivatives of M C and D O X 
generated from enzymatic reductions. These free radicals are strongly 
believed to induce some of the adverse side effects in hearts of cancer patients 
w h o are treated with M C and D O X . Since hearts have no or little endogenous 
defense systems against free radicals attack (Kaul et al., 1993), it is then 
suggested that exogenous antioxidants can be applied to cancer patients in 
combination with M C or D O X chemotherapy so as to remove the free radicals 
thus to minimize the adverse side effects of M C and D O X , at the same time, 
without reducing their antitumor effects. 
14 
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There are various approaches including incorporation of lipophilic 
antioxidants into membranes and lipids of the normal cells, extracellular anti-
radical interventions by targeting antioxidants, and scavenging of superoxide 
and/or hydroxyl radicals. The antioxidants can be used to prevent the 
generation of free radicals, or to capture the reactive intermediates (free 
radicals as well ) by binding with the intermediates and accepting the 
unpaired electrons, thus terminating the free radical reactions. 
It is well-known that diets rich in fruit and vegetables are protective 
against cardiovascular disease and certain forms of cancer and perhaps 
against other diseases as well. These protective effects have been attributed, in 
large part, to the antioxidants present including the antioxidant nutrients, 
vitamin C and p-carotene, but also the minor carotenoids, and plant phenolics 
such as the flavonoids and phenylpropanoids may have a significant role. The 
polyphenolic components of higher plants may act as antioxidants or as 
. agents of other mechanisms contributing to anticarcinogenic or 
cardioprotective action. Flavonoids, quercetin and genistein, were shown to 
inhibit the growth of colon adenocarcinoma cells, Caco-2 and HT-29, probably 
by inducing apoptosis, and the accumulation of ascorbic acid which is an 
important water-soluble antioxidant and an essential enzyme cofactor (Kuo et 
al., 1997). Flavonoids have also been' reported as having anti-inflammatory, 
antiallegic, antiviral, antibacterial activities as well (Bors et al., 1990). 
15 
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O n the other hand, phenolic compounds are known for their versatile 
primary antioxidant properties. Synthetic monodydric phenols, such as 
butylhydroxyl toluene (BHT) and 3-t-butylhydroxyanisole (BHA) effectively 
prevent auto-oxidation of fats (Stich, 1991), and cardiac toxicity caused by 
lipid peroxides (Nakaya et al, 1987). However, these phenols are insoluble in 
water and of little use in preventing toxicity of superoxide. Polyhydric 
phenols, such as n-propylgallate (NPG), has greater water solubility than 
monhydric phenols (Porter, 1980). The amphiphilic nature of PG, with both 
polar and nonpolar moieties spatially separated in the same molecule, 
provides high interfacial energy which facilitates accumulation at the water-
lipid interface (Porter, 1980). Accumulation of P G near the surface of the cell 
membranes should be useful in preventing the oxidation of membrane bound 
a-tocopherol by aqueous-phase radicals in a manner similar to that proposed 
for the antiperoxidative effects of some flavonoids, such as epicatechin gallate 
(Terao et al., 1994). Thus, P G can act simultaneously as a primary chain 
n,-
. Stopper and as a secondary inhibitor of chain branching in free radicals 
reaction propagation (Gutteridge, 1984). Also it is shown that P G can combine 
directly with the superoxide anion (Deeble, 1987). In addition to its direct 
radical scavenging properties, P G is also a potent inhibitor of free radical-
producing enzymes, such as lipoxygenase and cycloxygenase (Smith et al., 
1985). A combination of these properties provides the molecule with potent 
antimutagenic and anticarcinogenic activities (Hirose M . et al., 1993), and the 
ability to attenuate reperfusion injury in isolated liver preparations (Yones et 
al,, 1992). Present studies show that PG is also effective in promoting the 
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recovery of post-ischemic myocardium, probably due to its antioxidant 
behavior. 
Hence, the naturally occurring flavonoids and the synthetic phenolic 
compounds possess both antioxidant and anticarcinogenic effects. They then 
can be applied in combination with common chemotherapy so as to reduce 
the damages caused by free radical generating antitumor drugs, and also, 
enhance the antitumor effects of the drugs by inhibiting the proliferation of 
tumors at the same time. 
5. Effect of exogenous ATP on the antitumor activity of Doxorubicin 
and Mitomycin C 
5.1 Glutathione (GSH) and related enzymes 
. Glutathione (g-glutamylcysteinylglycine) is a tripeptide which is 
synthesized de novo chiefly in the liver and then translocated to plasma. 
Plasma glutathione (GSH) serves as a source for the constituent amino acids 
(principally cysteine) for G S H synthesis in peripheral organs (Meister, 1983). 
Glutathione may be turned over by translocation outside the cell by formation 
of thioesters or mixed disulfides, by reactions used to conjugate xenobiotics, 
or by oxidation by free radicals or peroxides to the disulfide, GSSG (the 
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The synthesis of G S H from its constituent amino acids occurs as a 
result of two ATP-requiring steps. The first step is catalyzed by the enzyme y-
glutamylcysteine synthetase; the second is catalyzed by glutathione 
synthetase (Meister and Anderson, 1983). The transport of intracellular G S H 
acts as a source of plasma G S H and GSSG and functions in the inter-organ 
transfer of cysteine sulfur. Also the transport of G S H may have a role in 
protecting the cell membrane by maintaining the integrity of essential thiol 
groups (Kosower and Kosower, 1983). 
G S H fulfills an important role in cellular defence mechanisms against 
hydrogen peroxide, organic peroxides and free radicals, produced as a 
consequence of aerobic metabolism (Meister and Anderson, 1983). The 
reduction of free radicals is nonenzymatic, whereas the reduction of peroxides 
is catalyzed by selenium-containing G S H peroxides (GPO) and by other 
proteins. The metabolism of these reaction intermediates is associated with 
V-
. G S H oxidation and majority of the GSSG produced is reduced by glutathione 
reductase (GR), a NADPH-dependent enzyme. Hence, cell survival in the 
presence of these reactive intermediates is dependent on the capacity of the 
G S H oxidation-reduction cycle, i.e. on the intracellular concentration of GSH, 
and GR, etc., as well as the ability to generate N A D P H via the pentose 
phosphate shunt (Kappus, 1986; Reed and Beatty, 1980). 
It is evident that G S H and its associated enzymes influence antitumor 
drug action in both normal and tumor tissues in a variety of ways, such as (a) 
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by reduction of drug cytotoxicity (increase in resistance), by detoxification of 
electrophilic species or of reactive intermediates. G S H may also reduce drug 
cytotoxicity by increasing repair of critical D N A lesions since it is utilized in 
the synthesis of D N A precursors (deoxyribonucleoside triphosphates) and by 
D N A repair enzymes (Lai et al., 1989); (b) G S H and its dependent enzymes 
may increase the activity of anticancer drugs by enhancing the formation of 
active species; (c) G S H may promote drug uptake; (d) alternations in G S H 
turnover due to drug therapy or drug modulators may influence the action of 
subsequent or concurrent therapeutic agents; (e) the overall efficacy of drugs 
might be altered depending on whether these changes occur in normal or 
tumor tissues. 
5.2 Glutathione (GSH) and the Anticancer Quinones 
Scientists have been looking for the role of G S H and its related enzyme 
V 
. cascades in the cytotoxicity of quinone-containing antitumor agents, such as 
Mitomycin C, Doxorubicin, etc., for mammalian cells and various tumor cell 
lines, both in vitro and in vivo. Recent studies have evaluated the effect of 
manipulating intracellular glutathione levels on the cytotoxicity of anticancer 
quinones. Using the y-glutamylcysteine synthetase inhibitor, L-buthionine 
sulfoximine (BSO), at concentrations which could deplete reduced glutathione 
(GSH) levels intracellularly without decreasing tumor cell viability, the 
cytotoxicity of D O X can be significantly increased in Chinese Hamster V79 
cells (Russo and Mitchell, 1985), in buccal mucosa carcinoma cells {Lee,et al., 
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1988), and in the P815 mouse mastocytoma (Arrick et al, 1983). It is believed 
that a substantial (>75%) decrease in intracellular G S H content is generally 
required before a significant increase in tumor cell cytotoxicity can be 
acquired. This suggests that because of the cyclical oxidation and reduction of 
G S H by the glutathione peroxidase cycle, G S H molecules can be efficiently 
recycled to reduce hydrogen peroxide or lipid hydroperoxides and that the 
absolute intracellular concentration of G S H must be markedly depleted. 
Moreover, it seems that enhancing intracellular thiol levels, either by 
pretreatment with thiol reducing agents such as N-acetylcysteine (NAC) or 
thiourea, or by over-expression of metallothioneins, can markedly decrease 
and in some cases eliminate the cytotoxic effects of D O X , M C and related 
compounds (Pommier et al., 1983; Doroshow, 1986a, b; Kelley et al" 1988). 
5.3 Glutathione and the cardiac toxicity of the anticancer drugs 
\-
The enzymatic antioxidant capacity of the mammalian heart, especially 
in comparison with the activity levels of the kidney and liver, is quite low. 
The superoxide dismutase (SOD) activity of the heart is 25-30% of that in the 
liver. Cardiac tissue contains essentially no glutathione-S-transferase (GST) 
and only 1-2% of the catalase levels found in hepatocytes (Lazzarino et al., 
1987). The normal level of G S H in the rat heart is about 8 m m o l / m g protein 
with a range of from 1.5 to 4 mmol/mg in other species (Thayer, 1988). These 
levels are substantially lower than those found in the liver and are similar to 
the range of G S H concentrations found to compromise the protection of 
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hepatocytes from the cytotoxic effect of D O X after exposure to nitrourea 
(Babson et al, 1981). This suggests that maintenance of intracellular peroxide 
homeostasis in the heart may depend on the efficient shuttling of a limited 
supply of G S H between G S H synthesis and metabolism enzymes. If the 
anticancer drugs redox cycling can transiently overcome the capacity of the 
heart to eliminate peroxides, in the presence of a limited concentration of 
S O D , conditions established would be favor the production of the hydroxyl 
radical by iron-catalyzed reaction. Hence, breakdown of G S H metabolism by 
reductions in the levels of either reduced glutathione or related enzymes 
would permit a markedly enhanced degree of cardiac tissue injury by an 
anticancer drug-stimulated free radical flux. Studies of anthracycline cardiac 
toxicity in vivo utilizing a single large dose of D O X to produce heart damage 
have revealed a significant, 60% drop in cardiac, but not liver, glutathione 
peroxidase levels for up to 72hr after administration of the drug (Doroshow et 
al., 1980). Furthermore, pretreatment of mice with pharmacological dose of 
•V 
vitamin E prior to doxorubicin blocked the drug-related inhibition of 
glutathione peroxidase activity (Doroshow and Locker, 1982). These results 
suggest that the oxidant stress produced in the anthracycline-treated heart 
drives the G S H related enzyme cascade toward the accumulation oxidized 
glutathione (GSSG) which is an indication that the peroxide detoxifying 
capacity of the myocyte has been exceeded. 
5.4 Glutathione depletion in tumor cells by exogenous ATP 
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The malignant cell differs from its normal counterpart in that it has 
lost, to some degree, responsiveness to homeostatic regulation of 
proliferation. However, the malignant cell originates from the normal cell, 
with essentially the same genetic array and the same biochemical machinery. 
It is found that the growth rate of a solid tumor decreases with increasing size 
and that the proliferating population decreases concomitantly. The sensitivity 
of a solid tumor to cyclophosphamide was shown to decrease in later stages 
of growth in conjunction with decreasing numbers of malignant cells in cycle 
in the advanced stage of tumor growth (Dewys, 1972). 
It is clear that chemotherapeutic selectivity in cancer is entirely 
dependent upon the proliferative state of the cells and not on any specific 
qualitative difference in physiology or biochemistry between normal and 
malignant cells (Perry and Yarbro, 1984). Chemotherapeutic agents do not 
discriminate between normal and neoplastic cells, and therefore, almost every 
V 
drug produces toxic side effects which limit the dose that can be 
administered, and limit the potential of these drugs. The primary targets for 
toxicity in the host include tissues with renewal cell populations, such as 
lymphoid tissues, bone marrow, and the epithelium of the gastrointestinal 
tract (Perry and Yarbro, 1984). Therefore, for many human tumors a given 
drug exposure may be equally cytotoxic to normal and malignant cells. Under 
such circumstances chemotherapy can only be effective when initiated at a 
time when the malignant cell number is below the threshold number of 
residual cells needed in the most susceptible, vital target tissue to repopulate 
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before irreversible toxicity. As the tumor cell number increases above this 
threshold number, chemotherapy will always kill the host at a drug 
concentration below that necessary to irradicate the tumor. Also the tumor 
can repopulate from even a single residual cell since the tumor does not 
perform a necessary function and thus there is no time limit for regeneration 
for the tumor. 
Since G S H and its related enzyme cascade are essential for the host 
against oxidative stress and the tumor cells to develop resistant against 
anticancer drugs, it has been questioned about the possibility of depleting or 
lowering the G S H levels, or inhibiting the G S H metabolism enzymes in 
tumor, at the same time, without interfering the that of the normal tissues, so 
as to discriminate the normal tissues from the tumor. Also, by weakening one 
of the cellular defense systems of the tumor, lower dosage of anticancer drugs 




A common G S H depleting agent, L-buthionine sulfoximine (BSO), has 
been used for its non-toxic and selective inhibitory effect on g-
glutamylcysteine synthetase (Meister, 1983). The depletion of tumor G S H by 
BSO in vivo decreases the rate of cetlular proliferation and inhibits cancer 
growth (Terradez et al., 1993). However, a major problem when using BSO or 
other GSH-depleting agents (i.e. the ab-unsaturated carbonyl compounds 
diethylmaleate or phorone), is that they decrease G S H levels in tumor and 
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non-tumor cells (Terradez et al., 1993). Nevertheless, exogenous A T P seems to 
offer a promising approach to the selective depletion of G S H in tumor. This is 
based on the administration of exogenous A T P which can decrease G S H 
contents in proliferating tumor cells without affecting G S H contents in normal 
cells, and also inhibits tumor growth (Lasso de la Vega et al., 1994). 
In m y research, G S H depletion in tumor cells in vivo is accompanied by 
chemotherapy in order to kill the tumor cells, and at the same time, use less 
amount of anticancer drugs. 
6. A i m of research 
In m y research, antioxidants are being investigated for their ability to 
remove or minimize the free radical mediated adverse side effects of 
Doxorubicin (DOX) or Mitomycin C (MC), but at the same time, without 
reducing their antitumor drug actions, both in vitro and in vivo. Also, 
V 
antioxidants which show antitumor activity are studied. For in vitro study, the 
cytotoxic effect and expression of superoxide dismutase (SOD) R N A are 
observed after D O X and/or M C plus antioxidants treatment on human 
normal and tumor cell lines. For in vivo study, antitumor effects and lipid 
peroxidation of heart of D O X and/or M C are investigated in tumor-bearing 
mice. The protective effects of the antioxidants are measured by observing the 
change of morphology in the hearts of these tumor-bearing mice. Also, 
Langendroff perfusion model is used to observe the free radical generation 
effects of D O X or M C and the protective effects of the antioxidants. Moreover, 
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exogenous A T P was used to suppress the growth of human cancer cells and 
to combined with D O X or M C in killing human cancer cell so as to establish 
strategies by which the normal cells could be distinguished from cancer cells. 
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CHAPTER TWO THE EFFECT OF ANTIOXIDANTS ON 
DOXORUBICIN- OR MITOMYCIN C-
INDUCED CYTOTOXICITY ON HUMAN 
TUMOR AND NORMAL CELL LINES 
2.1 Introduction 
Mammalian cells possess antioxidant defense systems that deal with 
reactive oxygen species produced as a consequence of aerobic metabolism, or 
that of metabolism of xenobiotics. One important family of enzymes that take 
up such role is the superoxide dismutase (SOD). This enzyme dismutates 
superoxide radical into hydrogen peroxide, which can be acted upon by other 
antioxidant enzymes, such as glutathione peroxidase and catalase. In human, 
there are three forms of superoxide dismutase : cytosolic Cu/ Zn-superoxide 
dismutase (Cu/Zn-SOD), mitochondrial manganese superoxide dismutase 
v 
(Mn-SOD), and extracellular superoxide dismutase (EC-SOD). The 
mitochondrial form of the enzyme, Mn-SOD, is inducible in response to 
agents that cause oxidative stress, such as radiation, tumor necrosis factor-a 
(TNF) and hypoxia (Perera et al., 1995). Hence Mn-SOD plays a central role in 
cellular defense against free radicals attack. Overexpression of Mn-SOD can 
protect the cells from oxidative stress-induced lipid peroxidation in 
membrane, peroxynitrie production and even apoptosis (Keller et al., 1998). 
There are correlations between Mn-SOD expression and increased resistance 
to cell injury and death. O n the other hand, tumor tissues expressing low 
26 
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levels of antioxidant enzymes, such as S O D and catalase, were shown to be 
more susceptible to free radical attacks, leading to elevated levels of reactive 
oxygen metabolites, resulting in damage to the key subcellular structures, 
such as D N A , cell membranes, and other vital cellular components (Guner et 
al, 1996). 
In this research, the effects of antioxidants, (+)-Catechin and N-Propyl 
gallate alone or combined with D O X and M C were studied in human 
hepatoma cell line (HepG2), transformed human normal endothelial cell line 
(ECV304) and rat myoblast cell line (H9c2). The cytotoxic effects of these 
antioxidants on the cell lines were studied. W e also investigate the probable 
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2.2 Materials and Methods 
Cell culture 
HepG2 (human hepatoma), ECV304 (human umbilical cord endothelial 
cell), H9c2 (rat myoblast) were grown in 75-cm2 polystyrene flasks (CORNING) 
in RPMI 1640 medium (GIBCOBRL), p H 7.4, supplemented with 10% FCS 
(GIBCOBRL) and 5% antibiotics (penicillin and streptomycin, GIBCOBRL). Cell 
cultures were maintained in a humidified atmosphere of 5% CO2 and 37^C. O n 
day of experiment, the cells were removed from the flasks with trypsin-EDTA 
(GIBCOBRL). They were plated at 2x104 cells per well on 96-well plates 
(CORNING). All the cell lines were obtained from ATCC. 
Drugs and treatment 
D O X (Sigma), M C (Sigma), (+)-Catechin (Sigma) and N-Propyl gallate 
(Sigma) were dissolved in sterile distilled water to a concentration of l m M and 
\-
diluted to the appropriate concentrations by the culture medium. 
Twenty four hours after plating the cells, the supernatant was discarded 
and replaced by fresh medium containing different concentrations of drugs. 
After a 24-hour incubation time at a humidified atmosphere of 5% CO2 and 37^C, 
the cell growth was monitored by the M T T assay. 
» 
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MTTAssay for measuring cell viability 
M T T (Sigma) was dissolved (5mg/ ml) in ice-cold PBS. The medium was 
discarded and the cells were washed twice with sterile PBS. Then 50jid M T T 
solution was added to each well. The plates were then incubated for 2 hours at 
370C. Then 150^1 D M S O was added to each well and all were incubated for 30 
minutes before O.D.540 was recorded by an ELISA plate reader (BIO-RAD). 
Expression ofresults and statistical significance 
The results were expressed as means 土 S.D. for the indicated numbers of 
different experiments. The statistical significance of differences was assessed by 
Student's t test. The percentage cell viability after each 24-hour treatment was 
calculated by dividing the difference of the absorbance of treated cells and 
untreated cells by the absorbance of control cells on day 0. 
Treatment of either ECV304 orHepG2 cells for Mn-SOD mRNA expression 
\-
• Either ECV304 or HepG2 cells were grown in 75-cm2 flasks (CORNING) 
as described in above section entitled “ Cell Culture “. Doxorubicin (DOX), 




1) N P G only; [NPG] = 0.5mg/ml (final concentration)； 
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2) D O X only; [DOX] = 6 ^ M (final concentration)； 
3) M C only; [MC] = lO^M (final concentration)； 
4) N P G + D O X ； [NPG] = 0.5mg/ml, [DOX] = 6^iM ； 
5) N P G + M C ； [NPG] = 0.5mg/mI, [MC] = 10|iM ； 
6) Medium only (negative control), 
and, 
1) Medium only (negative control)； 
2) 5 m M D O X ; 
3) 5 m M M C ； 
4) 5 0 0 m M Flavone ； 
5) D O X + 4 hr. + Flavone ； 
6) M C + 4 hr. + Flavone ； 
7) Flavone + 4 hr. + D O X ； 
8) Flavone + 4 hr. + M C ； 
V 
Isolation of total RNA from ECV304 and HepG2 cells by RNeasy Mini Kit 
(Qtagen) 
1. Adherent cells (lxlCF) in 75-cm2 culture flask were prepared. 
2. The culture medium was discarded and cells were washed with PBS twice. 
3. 600^ il buffer RLT (add lO^ il p-mercaptoethanol per 1ml of buffer RLT) was 
r 
added per flask. 
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4. The cells were scraped by a sterile cell scrapper. 
5. Lysate was pipetted directly onto a QIAshredder column (Qiagen) and 
centrifuged for 2 minutes at 8000 X g rpm to homogenise. 
6. Or the lysate could be homogenised by passing 10 times through a 21-G 
needle fitted to a syringe. 
7. 1 volume (about lml) of 70% ethanol was added to the homogenised lysate 
and mixed well by pipetting. 
8. U p to 700^ il of sample was applied each time, including any precipitate which 
may have formed to an RNeasy spin column, and centrifuged for 15 seconds 
at 8000Xg. 
9. 700^ il buffer R W 1 was pipetted onto the RNeasy column and centrifuged for 
15 secondsat8000Xg. 
10. RNeasy column was transferred into a new 2ml collection tube. 500^ il buffer 
RPE was pipetted onto the RNeasy column and centrifuged for 15 seconds at 
8000Xg. \ 
11.500ml buffer RPE was pipetted onto the RNeasy column. It was then 
centrifuged for 2 minutes at 8000 X g. 
12. RNeasy column was transferred into a new 1.5-mI collection tube and 30^1 of 
RNase-free water was pipetted directly onto the RNeasy membrane. It was 
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13. The R N A was stored at -7Q0C. 




10X M O P S buffer : it was prepared by mixing 0.2M M O P S (3-(N-Morpholino) 
propanesulfonic acid), 0.05M Sodium acetate, 0.01M E D T A 
and adjusted p H between 5.5 to 7 
37% Formaldehyde solution 
Ethidium bromide (lmg/ml) 
Loading buffer : it was prepared by mixing 0.8ml 10X M O P S buffer, 0.4ml 80% 
Glycerol, 0.4ml Bromophenol blue (saturated solution), 
1.4ml Formaldehyde (37%) and 4ml Formamide; it was 
stored at 0.5ml aliquots at -20^C. 
10X SSC 
Gel : 3g Agarose in 262ml DEPC-treated water; Agarose was dissolved in 
microwave and 30ml 10X M O P S was added; Agarose was cooled to 500Q 
5.4ml 37% Formaldehyde (giving the final concentration of 0.22M) was 
jr 
added; it was mixed by swirling. 
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B) Procedure 
1. Sample preparation : about 10 to 15fig of total R N A , or 1 to lO^g of m R N A 
was used for each sample. U p to lO^ il of sample could be used. 
2. 35^ il of loading buffer was add to each sample, it was mixed and heated to 
7Q0C for 2 minutes. 
3. Gel slab was placed into electrophoresis tank and covered with IX M O P S as a 
running buffer. 
4. 45|il of sample was loaded to each well. 
5. Gel was m n at 4 to 6 V / c m (i.e. 120 to 180 V) for 2 to 3 hours or until 
Bromophenol blue migrates about three fourth the length of the gel. 
6. Gel was photographed on U V transilluminator. 
7. The gel was blotted onto Nylon filters using an electric blotting apparatus for 
2 to 3 hours where 10X SSC was used for the blotting buffer. 




A) Probe labelling by Ready-to-Go DNA labelling Kit (-dCTP, Pharmacia) 
1. The contents were reconstituted by 20^1 distilled water. 
2. It was stood on ice for at least 5 minutes. 
r 
3. The D N A probe was denatured at the same time for 3 minutes at 95^C. It was 
immediately placed on ice for 2 minutes and centrifuged briefly. 
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4. 25^ il denatured D N A (concentration = 2ng/^il) was added. Then 5^ il 哪 dCTP 
(3,000 Ci/mmol, total 50 ^ iCi per sample) was added. 
5. It was mixed by pipetting up and down several times. Bubbles were removed 
by brief centrifugation. 
6. It was incubated in air bath at 37^C for 30 minutes. 
B) Purification by NucTrap Probe Purification Column (Stratagene) 
1. 80^ il TE buffer was added to reconstitute the column. 
2. The labelled D N A probe was added and the syringe was pushed. 
3. 80^ il TE buffer was added. 
4. The syringe was pushed to collect all the contents. 
C) Hybridization using ExpressHyb Hybridization Solution (Clontech) 
1. The Hybridization solution was warmed at 70^C for complete dissolving. 
2. About 10ml of hybridization solution was added and the membrane was pre-
hybridized at 65^C for 30 minutes. 
3. The labelled D N A was denatured at 95^C for 5 minutes. It was chilled quickly 
on ice. 
4. The probe was added to 10ml 65^0 pre-warmed fresh hybridization solution. 
It was mixed thoroughly. 
5. It was incubated at 65^C for 1 hour. 
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7. The membrane was wrapped. 
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2.3 Results 
Effect ofDOX and MC on HepG2 and ECV304 cells 
After 24 hours incubation under aerobic condition, the I C 5 0 of 
Mitomycin C (MC) and Doxorubicin (DOX) on human hepatoma cells 
(HepG2) were found to be 3^iM and 5^iM respectively (Figure 2.3.1 and 
2.3.2). 
Under the same condition, the I C 5 0 of M C and D〇X on human 
normal endothelial cells ECV304 were 5 ^ M and 15^M respectively (Figure 
2.3.3 and 2.3.4). This result indicates that M C and D O X are also toxic to 
normal cells. Their toxicities, as indicated by the value of I C 5 0 , on normal 
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Figure 2.3.1 Effect of Mitomycin C on HepG2 cells. 
H u m a n hepatoma cells (HepG2) were grown in RPMI 1640 medium and 
supplemented with 10% FCS and 5% antibiotics. They were plated at 
2x104 cells per well in 96-well plates, and incubated overnight in a 
humidified atmosphere at 37。C and 5%CC>2. Mitomycin C dissolving in 
the same medium was added 50^ il per well. The cells were then incubated 
under the same condition for 24 hours. The medium was discarded and 
the cells were washed twice with PBS. M T T assay was used to measure 
the viability of the remaining cells. O.D.540 was converted to percentage 
cell viability with reference to the control in which no Mitomycin C was 
added. Vertical bar represented one standard error. 
•% 
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Figure 2.3.2 Effect of Doxorubicin on HepG2 cells. 
H u m a n hepatoma cells (HepG2) were grown in RPMI 1640 medium and 
supplemented with 10% FCS and 5% antibiotics. They were plated at 
2x104 cells per well in 96-w'ell plates, and incubated overnight in a 
humidified atmosphere at 37°C and 5%CO2. Doxorubicin dissolving in the 
same medium was added 50^ il per well. The cells were then incubated 
under the same condition for 24 hours. The medium was discarded and 
the cells were washed twice with PBS. M T T assay was used to measure 
the viability of the remaining cells. O.D.540 was converted to percentage 
cell viability with reference to the control in which no Doxorubicin was 
tr 
added. Vertical bar represented one standard error. 
« 
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Figure 2.3.3 Effect of Mitomycin C on ECV304 cells. 
H u m a n umbilical cord endothelial cells (ECV304) were grown in RPMI 
^ 
1640 medium and supplemented with 10% FCS and 5% antibiotics. They 
were plated at 2x10^ cells per well in 96-well plates, and incubated 
overnight in a humidifed atmosphere at 37。C and 5%COi. Mitomycin C 
dissolving in the same medium was added 50^1 per well. The cells were 
then incubated under the same condition for 24 hours. The medium was 
discarded and the cells were washed twice with PBS. M T T assay was used 
to measure the viability of the remaining cells. O.D.s40 was converted to 
percentage cell viability with reference to the control in which no 
Mitomycin C was added. Vertical bar represented one standard error. 
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Figure 2.3.4 Effect of Doxorubicin on ECV304 cells. 
H u m a n umbilical cord endothelial cells (ECV304) were grown in RPMI 
'K' 
. 1640 medium, supplemented with 10% FCS and 5% antibiotics and were 
plated at 2x104 cells per well in 96-well plates, and incubated overnight in 
a humidified atmosphere at 37^C and 5%C〇2. Doxorubicin dissolving in 
the same medium was added 50^ il per well. The cells were then incubated 
under the same condition for 24 hours. The medium was discarded and 
the cells were washed twice with PBS. M T T assay was used to measure 
the viability of the remaining cells. O.D.s40 was converted to percentage 
cell viability with reference to the control in which no Doxorubicin was 
added. Vertical bar represented one standard error. 
•% 
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Effect of(+)-Catechin on the cytotoxicity ofMC on HepG2 and ECV304 cells 
Under aerobic condition, w e found that for concentrations 0.43mM-
1.72mM, (+)-Catechin was cytotoxic to human hepatoma HepG2 cells but not 
to human normal endothelial cells ECV304 (Figure 2.3.5 and 2.3.6). This 
implies that this flavonoid antioxidant can kill tumor cells but it is not toxic to 
normal cells. Moreover, (+)-Catechin at concentrations between 0.86mM and 
0.054mM could protect the ECV304 cells against the cytotoxicity of Mitomycin 
C (MC) by increasing the ECV304 cell viability from 60% to over 80%, 
comparing the dose-response of ECV304 cells to M C treatment alone (Figure 
2.3.6 and 2.3.3). With same treatment under aerobic condition, the viability of 
HepG2 cells under M C treatment was only increased from 50% to 60% by 
additional treatment of (+)-Catechin (Figure 2.3.5 and 2.3.1). 
This result indicates that (+)-Catechin can protect normal ECV304 cells 
from the damage of M C and on the other hand, this antioxidant may help M C 
r-
to kill hepatoma HepG2 tumor cells. 
» 
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Figure 2.3.5 Effect of (+)-Catechin (CAT) alone and (+)-Catechin 
(CAT) plus Mitomycin C on HepG2 cells. 
[Mitomycin C] : 3^iM 
\-
[Catechin]: 
1: 3.44mM; 6: 0.108mM; 
2: 1.72mM; 7: 0.054mM; 
3: 0.86mM; 8: 0.027mM; 
4: 0.43mM; 9: 0.013mM; 
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Figure2.3.6 Effect of (+)-Catechin (CAT) alone and (+)-Catechin 
(CAT) plus Mitomycin C (MC) on ECV304 cells. 
V 
[Mitomycin C]: 3^iM 
[Catechin]: 
1: 3.44mM; 6: 0.108mM; 
2: 1.72mM; 7: 0.054mM; 
3: 0.86mM; 8: 0.027mM; 
4: 0.43mM; 9: 0.013mM; 
5: 0.215mM; 10: 0.007mM; 
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Effect ofN'Propvl gallate on the cytotoxicity ofMC on HepG2 and ECV304 
cells 
For concentrations less than 0.4mM, N-Propyl gallate did not show 
cytotoxicity to ECV304 cells (Figure 2.3.7) whilst it was cytotoxic to HepG2 
cells (Figure 2.3.8). However, only at lower concentrations of N-Propyl 
gallate, it could protect the ECV304 cells from cytotoxicity of M C (Figure 
2.3.7). W e found that in the combined treatment on HepG2 cells, N-Propyl 
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Figure 2.3.7 Effect of N-Propyl gallate (NPG) alone and N-Propyl 
gallate (NPG) plus Mitomycin C (MC) on ECV304 
cells. 
[Mitomycin C]: 3^iM 
V 
[NPG]: 
1： 3.3mM; 6: 0.103mM; 
2: 1.65mM; 7: 0.052mM; 
3: 0.825mM; 8: 0.026mM; 
4: 0.413mM; 9: 0.013mM; 
5: 0,206mM; 10: 0.006mM; 
9 
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Figure 2.3.8 Effect of N-Propyl gallate (NPG) alone and N-Propyl 
gallate (NPG) plus Mitomycin C (MC) on HepG2 cells. 
[Mitomycin C]: 3^iM 
[NPG]: 、 
1: 3.3mM; 6: 0.103mM; 
2: 1.65mM; 7: 0.052mM; 
3: 0.825mM; 8: 0.026mM; 
4: 0.413mM; 9: 0.013mM; 
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Effect of(+)'Catechin on the cytotoxicitu ofDOX on HepG2 and ECV304 cells 
W e also observed that (+)-Catechin could greatly enhance the cytotoxic 
effect of Doxorubicin (DOX) on HepG2 cells (Figure 2.3.10). This effect was 
also found in combined treatment of D O X and N-propyl gallate on HepG2 
cells (Figure 2.3.11). In contrast, (+)-Catechin or N-propyl gallate could 
protect normal ECV304 cells from the damages of D O X at various degrees 
(Figure 2.3.9 and Figure 2.3.12 respectively). 
V 
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Figure 2.3.9 Effect of (+)-Catechin (CAT) alone and (+)-Catechin 




1: 3.44mM; 6: 0108mM; 
2: 1.72mM; 7: 0.054mM; 
3: 0.86mM; 8: 0.027mM; 
4: 0.43mM; 9: 0.013mM; 
5: 0.215mM; 10: 0.007mM; 
•« 
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Figure 2.3.10 Effect of (+)-Catechin (CAT) alone and (+)-Catechin 




1: 3.44mM; 6: 0.108mM; 
2: 1.72mM; 7: 0.054mM; 
3: 0.86mM; 8: 0.027mM; 
4: 0.43mM; 9: 0.013mM; 
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Figure 2.3.11 Effect of N-Propyl gallate (NPG) alone and N-Propyl 




1: 3.3mM; 6: 0103mM; 
2: 1.65mM; 7: 0.052mM; 
3: 0.825mM; 8: 0.026mM; 
4: 0.413mM; 9: 0.013mM; 
5: 0.206mM; 10: 0.006mM 
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Figure 2.3.12 Effect of N-Propyl gallate (NPG) alone and N-Propyl 
gallate (NPG) plus Doxorubicin (DOX) on ECV304 cells. 
[Doxorubicin]: 5 ^ M 
[NPG]: 
1: 3.3mM; 6: 、0.103mM; 
2: . 1.65mM; 7: 0.052mM; 
3: 0.825mM; 8: 0.026mM; 
4: 0.413mM; 9: 0.013mM; 
5: 0.206mM; 10: 0.006mM; 
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Effect ofN-Propyl gallate on the cytotoxicity ofDOX and MC on H9c2 cells 
The probable protective effect of N-propyl gallate against DOX- or MC-
induced damage in normal cells was further tested. In rat myoblasts (H9c2), 
two concentrations of N-propyl gallate, i.e. 4.1mM and 16.5mM, reduced the 
cytotoxic effect of D O X (6^iM) and M C (lO^iM) as demonstrated by the 
decreasing of the inhibitory index. D O X or M C was toxic to H9c2 in the 
absence of N-propyl gallate under aerobic conditions (Figure 2.3.15). M C at 
concentration of lO^iM showed a 35% of cytotoxicity on H9c2 cells (Figure 
2.3.13). D O X at concentration of 6^iM showed a 50% of cytotoxicity on H9c2 
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Figure 2.3.13 Effect of Mitomycin C (MC) on the growth of rat 
myoblast cells (H9c2). 
Rat myoblast cells (H9c2) were grown in RPMI1640 with 10% FCS and 5% 
antibiotics. They were plated at 1x104 cells per well in 96-well plates, and 
V 
incubated overnight in a humidified atmosphere at 37°C and 5%COi. 
Mitomycin C dissolving in the same medium was added 50^ il per well. 
The cells were then incubated under the same condition for 24 hours. The 
medium was discarded and the cells were washed twice with PBS. M T T 
assay was used to measure the viability of the remaining cells. O.D.s40 was 
converted to percentage cell viability with reference to the control in 
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Figure 2.3.14 Effect of Doxorubicin (DOX) on the growth of rat 
myoblast cells (H9c2). 
Rat myoblast cells (H9c2) were grown in RPMI 1640 with 10% FCS and 5% 
antibiotics. They were plated at lxlO^ cells per well in 96-well plates, and 
incubated overnight in a humidified atmosphere at 37°C and 5%CC>2. 
V 
Doxorubicin dissolving in the same medium was added 50^1 per well. The 
cells were then incubated under the same condition for 24 hours. The 
medium was discarded and the cells were washed twice with PBS. M T T 
assay was used to measure the viability of the remaining cells. O.D.s40 was 
converted to percentage cell viability with reference to the control in 
which no Doxorubicin was added. Vertical bar represented one standard 
error. 
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Figure 2.3.15 Effect of Mitomycin C (MC) alone an^or N-Propyl 
gallate (NPG) on rat myoblast cells (H9c2). 
[MC]: lO^iM, 
[DOX]: 6^M, 
[NPG]: 0.41mM to 16.5mM. 
Inhibitory index is defined as the difference between the cell viability of 
untreated group and that of the MC-treated group or the M C + N P G -
treated group. A positive value means the cell viability of drug-treated 
group is higher than the untreated group. A negative value means the cell 
viability of drug-treated group is lower than that of the untreated group. 
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Effect of N'Propyl gallate and flavone on the expression of Mn-SOD 
expression in HepG2 and ECV304 cells 
The mechanism by which antioxidants such as N-propyl gallate 
(NPG) protect normal human endothelial cells (ECV304) from DOX- or 
MC-induced cytotoxicity was studied. The expression of m R N A of 
antioxidant enzyme, Mn-SOD, was investigated by Northern 
hybridization. 
In human ECV304 cells, the addition of N P G induced the 
expression of M n - S O D m R N A in DOX- or MC-treated cells (Figure 2.3.16 
and 2.3.17), which may hence protect the ECV304 cells from the free 
radicals attack of D O X and M C . However, this induction was very low in 
human HepG2 cells (Figure 2.3.16 and 2.3.17). W e found that N P G alone 
was also capable of inducing Mn-SOD m R N A expression in ECV304 cells 
but not in HepG2 cells (Figure 2.3.16). 
Moreover, flavone, another kind of flavonoids, was capable of 
V 
inducing Mn-SOD m R N A expression in ECV304 cells under combined 
treatment with D O X or M C (Figure 2.3.18). This induction was 
independent of the sequence of addition of drugs and flavone. 
9 
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Figure 2.3.16 Northern Blot Hybridization of Mn-SOD mRNA 
expression in ECV304 and HepG2 treated with 
Doxorubicin (DOX), or Mitomycin C (MC) and N-
Propyl gallate (NPG) separately. 
(started from left) 
Lane 1 ECV304, control ； 
Lane 2 ECV304, lO^iM D O X ； 
Lane 3 ECV304, 6^iM M C ； 
Lane 4 ECV304, 2.35mM N P G ； 
Lane 5 HepG2, control ； 
Lane 6 HepG2, lO^iM D O X ； 
Lane 7 HepG2, 6^iM M C ； , 
Lane 8 HepG2, 2.35mM N P G 
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Figure 2.3.17 Northern Blot Hybridization of Mn-SOD mRNA 
expression in ECV304 and HepG2 treated concomitantly 
with Doxorubicin (DOX), or Mitomycin C (MC) and N-
Propyl gallate (NPG). 
V 
(started from left) 
Lane 1 ECV304, lO^iM M C + 2.35mM N P G ； 
Lane 2 ECV304, 6^iM D〇X + 2.35mM N P G ； 
Lane 3 HepG2, lO^iM M C + 2.35mM N P G ； 
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Figure 2.3.18 Northern Blot Hybridization of Mn-SOD mRNA 
expression in ECV304 treated concomitantly with 
Doxorubicin (DOX), or Mitomycin C (MC) and flavone. 
� -
(started from left) 
Lane 1 control ； 
Lane 2 5^iM D O X ； 
Lane 3 5[iM M C ； 
Lane 4 500^iM Flavone ； 
Lane 5 D O X treated for 4 hr. + Flavone ； 
Lane 6 M C treated for 4 hr. + Flavone ； 
Lane 7 Flavone treated for 4 hr. + D O X ； 
Lane 8 Flavone treated for 4 hr. + M C 
59 
Combined treatment in cell lines 
-^MB^^aa8a88aBeaBsaaxa8=aa a=aaax=8= 
2.4 Discussion 
Flavonoids and gallic acids are polyphenolic natural compounds found in 
fruits and vegetables. (+)-Catechin and N-Propyl gallate are two of the members 
of such compounds. They have gained recent interest because of their broad 
pharmacological activities, namely their antioxidant activity and antitumor 
activity. (+)-Catechin when given in diet showed a strong protection against 
heme protein oxidation (Chen and Tappel, 1994), and human plasma oxidation 
(Lotito and Fraga, 1998). These structurally related flavonoids can undergo 
complex reaction in protecting low-density lipoprotein against transition metal 
induced oxidation (Brown et al., 1998; Yoshino and Murakami, 1998). 
In addition to their antiradical effects, flavonoids show antiproliferative 
effect on various tumors. In human breast cancer cells, flavonoids exert large 
antitumor effects by an induction of cell cycle arrest and inhibition of certain 
enzymes, such as cell cycle-related kinases (Zi et al, 1998). Our data showed that 
^-
(+)-Catechin and n-propyl gallate both possess antitumor effect in vitro on 
human hepatoma (HepG2) under aerobic condition (Figure 2.3.5 to 2.3.8). The 
mechanism of their antitumor activity is not known yet. However, some 
antioxidants possessing planar and ring shapes, such as tamoxifen, were 
f 
suggested to exert their antitumor effect by decreasing the membrane fluidity 
and recovering the contact inhibition properties of normal cells, thus suppressing 
the proliferation of tumor cells by intercalating the planar ring into the 
« 
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hydrophobic lipid bilayers of the tumor cells (Wiseman, 1994; Wiseman and 
Quinn , 1994). Though this hypothesis still needed to be proved by further 
investigation, the fact that (+)-Catechin and n-propyl gallate possessing planar 
shapes is obvious. 
D O X and M C are well known for their adverse free radical-production 
side effects under aerobic conditions (Keizer et al., 1990; Rockwell et al, 1993). 
Combined treatment of D O X and M C with (+)-Catechin and n-propyl gallate 
was studied in present study. The protective effect of these two antioxidants on 
the cytotoxicity of D O X and M C on normal endothelial cells, ECV304 was 
observed under aerobic conditions (Figures 2.3.6, 2.3.7, 2.3.9, 2.3.12). The free 
radicals generated by D O X and M C could be removed by antioxidants in 
ECV304 cells. However, the cytotoxic effects of D O X and M C on HepG2 cells 
were enhanced but not reduced by the two antioxidants used under aerobic 
condition. W e only concerned about the cytotoxic effect of D O X and M C under 
aerobic environment because most of the normal tissues were highly oxygenated 
*K-
and thus provided an aerobic condition favoured the induction of free radicals 
by the drug action of D O X and M C . W e suggested that these antioxidants 
scavenged the unpaired electrons of the free radicals produced by D O X and M C , 
and stabilised these free radicals to non-toxic metabolites. The cytotoxic effect of 
D O X and M C on HepG2 cells was not reduced by (+)-Catechin and n-propyl 
gallate because these antioxidants stabilised the free radicals induced, such as 
hydroxyl radicals, but could not conjugate to the active intermediates of D O X 
* 
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and M C . The activated intermediates of D O X and M C can exert their antitumor 
activities by intercalating the D N A of fast growing cancer cells and exert their 
antitumor activity. 
The activity and expression of Mn-SOD directly affect the host or cells 
against the oxidative stress. In order to evaluate the protective effect of the 
antioxidants on normal human cells, w e studied the expression of Mn-SOD 
m R N A in tumor and normal cells, treated with D O X , M C , n-propyl gallate or 
flavone. It has been reported that mice overexpressing Mn-SOD have prolonged 
survival under free radical-induced hyperoxic lung injury comparing to control 
(Ho et alr 1998). However, elevated Mn-SOD m R N A levels and activities were 
also found to be related to the resistance to chemotherapeutic agents in some 
malignant cells (Kinnula et al., 1998). 
Our data indicated that Mn-SOD m R N A expression was elevated by N P G 
in human transformed normal endothelial cells, ECV304, but not in human 
hepatoma, HepG2 (Figure 2.3.16). Also, flavone, one of the natural flavonoids, 
*K. 
‘ was also found to elevate the Mn-SOD m R N A expression in ECV304 cells (Figure 
2.3.17). In fact, many researchers have reported that transcription of genes 
encoding flavoprotein-type enzymes, such as DT-diaphorase, which protected 
cells against mutagenicity and carcinogenicity causing by free radicals were 
activated in response to exposure to phenolic antioxidants or chemoprotectors, 
such as B H A (Belinsky and Jaiswal, 1993; Uda et al., 1997). These enzymes were 
believed to be involved in detoxification of xenobiotics and drugs, such as 
« 
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alkylating aziridinyl benzoquinones (Mitomycin C). However, M n - S O D was 
considered as a cellular defence to maintain the balance of oxidant and 
antioxidant capacity of the host; and its low level in some carcinoma tissues 
could lead to elevated levels of reactive oxygen metabolites, either from 
radiotherapy or chemotherapeutic agents, resulting in high sensitivity of tumor 
tissues to such therapy (Guner et al, 1996). Suppression of the Mn-SOD levels in 
tumor cells made them more susceptible to the cytotoxic effect of Mitomycin C 
(Nagasawa and Little, 1983). 
In our research, w e found that N P G could elevate the Mn-SOD m R N A 
levels in human normal ECV304 cells, but N P G did not elevate the Mn-SOD 
m R N A levels in human hepatoma HepG2 cells. Although the mechanism by 
which N P G exhibit different effects in stimulating Mn-SOD m R N A expression in 
normal human ECV304 and human tumor HpeG2 is not known, w e suggested 
that N P G may be used as an effective antioxidant in protecting the host against 
the adverse free radical attack generated from the aerobic biotransformation in 
V 
drug actions of D O X and M C . However, w e have only tried one concentration of 
N P G . Further investigation is needed to study the dose response of N P G in 
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CHAPTER THREE STUDY OF CARDIOPROTECTIVE EFFECTS OF 
ANTIOXIDANTS AGAINST DOXORUBICIN-
OR MITOMYCIN C-INDUCED TOXICITY BY 
LANGENDORFF PERFUSED ISOLATED RAT 
HEART MODEL 
3.1 Introduction 
The Langendorff perfused isolated rat heart model is widely used to 
investigate a broad variety of questions both in physiological-
pharmacological research and in etiology of myocardial dysfunction and 
cardiac pathology. This model can be used as a predictive model for the pre-
clinical evaluation of anthracycline cardiotoxicity i.e., drug-induced 
cardiomyopathies, and the means of preventing it by studying the functional 
parameters of perfused isolated rat hearts (Pouna et al, 1995). This appears to 
V 
be a valuable model for screening new anthracyclines and testing strategies 
for overcoming and unraveling anthracycline cardiotoxicity. This ex vivo 
whole-heart model also provides invaluable tool in the study of ischemic-
reperfusion cardiac injury and the ways to attenuate. Besides, this model 
provides an alternative way for evaluating the quality and improvement of 
preservation fluid in organ transplantation (Mankad et al., 1992). 
In the setup of this model, it allows the use oxygenated perfusion fluid, 
i.e. Krebs-Henseleit buffer, p H 7.4, by bubbling the fluid with carbogen (95% 
O2 and 5% CO2). The perfusion fluid can be kept at 37^0 by a thermostat. The 
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contraction of the heart will be transmitted by a transducer and recorded on 
graph as contraction force by its amplitudes. Bolus injection of drugs 
dissolved in the perfusion fluid can be achieved by a channel opened next to 
the cannula which connects to the perfused rat heart. 
The cardiotoxicity of Doxorubicin and Mitomycin C remains a clinical 
problem of major importance. As these drugs are required for the treatment 
of hematological malignancies and solid tumors, their cumulative toxicity on 
the myocardium prevents their use at their maximum myelotoxic doses 
during the optimal number of courses required. Though dose-reduction 
protocols have been proposed to avoid the risk of delayed cardiac toxicity, 
this might be at the expense of the reduction of the antitumor activity of these 
drugs. Numerous aims have been developed to obtain greater potency of 
these drugs with reduced cardiac toxicity. It is well known that the cardiac 
toxicity of Doxorubicin and Mitomycin is related to their free radicals 
generation. Hence, application of antioxidants which are capable of 
. .^-
scavenging these free radical species by various mechanisms is suggested 
during the chemotherapy. 
In this research, administration of antioxidants, such as (+)-Catechin 
and N-Propyl gallate, was introduced so as to reduce the cardiac toxicity of 
both Doxorubicin and Mitomycin C. Co-treatment of antioxidants with these 
two anthracyclines was also studied. Both (+)-Catechin and N-Propyl gallate 
were dissolved in the perfusion fluid, i.e. Krebs-Henseleit buffer, and directly 
co-perfused with either Doxorubicin or Mitomycin C into the isolated rat 
heart. The effect of these antioxidants on the isolated rat heart was measured 
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by the Flow Rate of perfusate passing through the heart, the Contraction 
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3.2 Materials and Methods 
Animals 
Male Sprague-Dawley rats (8 weeks; 250g each) were supplied by the 
Animal House of The Chinese University of Hong Kong. They were kept on a 
12 h-light/12 h-dark cycle and fed on a stock laboratory diet (PICOLAB). 
Drugs preparation 
Doxorubicin (Sigma) and Mitomycin C (Sigma) were dissolved 
separately in ice-cold distilled water and made up to a concentration of l m M . 
They were diluted to lO^M working solution by perfusion solution. (+)-
Catechin (Sigma) was dissolved in distilled water and made to l m M . It was 
diluted to 50^iM working solution by perfusion solution. The perfusion 
solution was the modified Krebs-Henseleit solution containing : 118 m M 
NaCl, 4.7 m M KC1, 2.5 m M CaCl2,1.2 m M KH2PO4,1.2 m M MgSO4, 25 m M 
•K-
NaHCO3,11 m M Glucose, pH 7.4. 
Perfusion ofrat isolated hearts 
The following procedures have obtained the approval of Animal 
Research Ethics Committee of The Chinese University of Hong Kong. 
Rats were sacrificed by cervical dislocation. The heart was quickly 
removed and briefly soaked in modified Krebs-Henseleit solution at 4PC. 
Coronary perfusion was initiated through a short cannula in the aortic root 
and maintained in a non-recirculating way by the Langendorff technique. 
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Contraction force was measured by a Force Displacement Transducer 
(GRASS, Astro-Med Inc.) connected to the rat heart. The signal was amplified 
by a D C Amplifier ( H A R V A R D A P P A R A T U S ) and displayed by a Chart 
Annotator ( H A R V A R D APPARATUS). After 20 minutes stabilization with 
buffer, either Doxorubicin, Mitomycin C or Doxorubicin + (+)-Catechin or 
Mitomycin C + (+)-Catechin was co-perfused with the buffer. At every 30 
minutes, the perfusion of drugs was withdrawn and 10 minutes stabilization 
was allowed. Then the force of contraction and the flow rate were measured 
within 5 minutes. The whole course of perfusion of one rat heart would last 
for 1.5 hours depending on the sensitivity of the heart upon the treatment. 
The force of contraction and the flow rate after the first 30 minutes 
stabilization were also recorded as well. 
Statistical analysis ofthe data 
Statistical comparisons between non-coperfused and coperfused 
V 
groups were made by Student's t test. All data were expressed as the mean 
value + S.D. Statistical significance was determined as a p value below 0.05. 
r 
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3.3 Results 
By using the Langendorff model of rat heart perfusion, cardiotoxic 
effects of Doxorubicin (DOX) and Mitomycin C (MC) were observed. Three 
parameters of the rat cardiac performance under treatment were recorded. 
They were the Contraction Force, Beat Rate and Flow rate of perfusate 
passing through the hearts. All the perfused hearts were allowed a 20-minute 
stabilization with Krebs-Henseleit solution before drug treatment. The cardiac 
performance of individual rat heart after 30 minutes drug treatment was 
compared to that of the same heart after the first 20-minute stabilization. Thus 
the results were expressed as the percentage of the initial performance. 
Effect of(+)'Catechin in the Contraction Force ofrat heart 
After the later 30 minutes perfusion with Krebs-Henseleit solution, the 
Contraction Force of the normal untreated rat hearts showed no difference 
compared with that of the same hearts recorded at the end of the first 20-
minute (Figure 3.3.1). 
Mitomycin C in a concentration of lO^iM and a perfusion period of 30 
minutes, caused cardiac toxic effects to the rat hearts by reducing their 
Contraction Force to about 57% of that of the initial period (Figure 3.3.1). This 
cardiac toxicity of M C could be nearly eliminated and recovered by (+)-
Catechin. In a concentration of lOO^iM and perfused concomitantly with M C , 
(+)-Catechin recovered the Contraction Force 'to about 80% of that of the 
initial value (Figure 3.3.1). 
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Doxorubicin in a concentration of 10|iM and a perfusion period of 30 
minutes, caused cardiac toxic effects to the rat hearts by reducing their 
Contraction Force to about 55% of that of the untreated one (Figure 3.3.1). 
This cardiac toxicity of D O X could be nearly eliminated and recovered by (+)-
Catechin. In a concentration of lOO^iM and perfused concomitantly with D O X , 
(+)-Catechin recovered the Contraction Force to about 82% of that of the 
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Figure 3.3.1 Percentage Recovery of Contraction Force in rat hearts 
perfused with DOX or MC alone, and concomitantly 
with (+)-Catechin. 
Each rat heart was perfused with Krebs-Henseleit solution for 20 minutes for 
V 
stabilization. D O X , M C and (+)-Catechin were freshly prepared to 
concentrations of lO^iM, lO^iM and 100^M respectively with the same solution 
just prior to use. In M C + C A T and D O X + C A T groups, M C or D O X were 
perfused with C A T concomitantly in the same solution. All the rat hearts 
were perfused for 30 minutes with these drugs. The Contraction Force 
recorded at the end of the 30-minute was expressed as the percentage of that 
record at the end of the 20-minute. Data were expressed as mean 土 S.D. 
• 
Significant difference was compared between M C + C A T group and M C 
group, and, D O X + C A T group and D O X group ( * 尸 < 0.001; n = 8 )• 
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Effect of(+>-Catechin in the Flozv Rate ofperfusate through rat hearts 
The Flow Rate of the perfused rat hearts was recorded as the volume 
(ml) of perfusate passing through the rat hearts and collected in 1 minute. 
After 30 minutes of perfusion with modified Krebs-Henseleit solution, 
the mean beat rate of normal untreated rat hearts was about 95% of that of the 
same hearts recorded after the first 20-minute stabilization (Figure 3.3.2). 
Mitomycin C in a concentration of lO^iM decreased the Flow Rate of rat 
hearts to 46% of that of the initial value (Figure 3.3.2). (+)-Catechin (lOO^iM) 
when co-perfused with M C , restored the Flow Rate to 78% of that of the initial 
value (Figure 3.3.2). 
Doxorubicin in a concentration of 10|iM reduced the Flow Rate of rat 
hearts to 41% of that of the initial value (Figure 3.3.2). (+)-Catechin (lOO^M) 
when co-perfused with D O X , restored the Flow Rate to 84% of that of the 
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Figure 3.3.2 Percentage Recovery of Flow Rate in rat hearts perfused 
with DOX or MC alone, and concomitantly with (+)-
Catechin. 
Each rat heart was perfused with Krebs-Henseleit solution for 20 minutes for 
stabilization. D O X , M C and (+)-Catechin were freshly prepared to 
concentrations of 10|iM, lO^iM and lOO^iM respectively with the same solution 
just prior to use. In M C + C A T and D O X + C A T groups, M C or D O X were 
perfused with C A T concomitantly in the same solution. All the rat hearts 
were perfused for 30 minutes with these drugs. The Flow Rate recorded at the 
end of the 30-minute was expressed as the percentage of that record at the 
end of the 20-minute. Data were expressed as mean 土 S.D. Significant 
difference was compared between M C group and M C + C A T group, and, D O X 
group and D O X + C A T group ( * p < 0.1; n = 8 )• 
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Effect of(+)'Catechin in the BeatRate ofrat hearts 
The heart beat rate of the perfused rat hearts was recorded as the 
number of beats per minute. 
After 30 minutes of perfusion with Krebs-Henseleit solution, the mean 
beat rate of normal untreated rat hearts was about 95% of that of the same 
hearts recorded after the first 20-minute stabilization. 
Mitomycin C in a concentration of lO^iM and perfused for 30 minutes, 
caused a reduction of beat rate of rat hearts to 85% of the initial value (Figure 
3.3.3). The simultaneous addition of lOO^iM (+)-Catechin restored the beat rate 
to 94% of the initial value (Figure 3.3.3). This almost restored the value to that 
of the normal ones, i.e.95% of the initial value (Figure 3.3.3). 
Doxorubicin in a concentration of lO^iM and perfused for 30 minutes, 
reduced the beat rate of rat hearts to 69% of the initial value (Figure 3.3.3). The 
co-perfusion of lOOp,M (+)-Catechin restored the beat rate to 81% of the initial 
V 
value (Figure 3.3.3) 
w 
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Figure 3.3.3 Percentage Recovery of Heart Beat Rate in rat hearts 
perfused with D O X or M C alone, and concomitantly 
with (+)-Catechin. 
Each rat heart was perfused with Krebs-Henseleit solution for 20 minutes for 
stabilization. D O X , M C and (+)-Catechin were freshly prepared to 
concentrations of lO^iM, lO^iM and lOO^iM respectively with the same solution 
just prior to use. In M C + C A T and D O X + C A T groups, M C or D O X were 
perfused with C A T concomitantly in the same solution. All the rat hearts 
were perfused for 30 minutes with these drugs. The Heart Beat Rate, i.e. 
number of beats per minute, recorded at the end of the 30-minute was 
expressed as the percentage of that record at the end of the 20-minute. There 
were 8 rats in each group. Data were expressed as mean 土 S.D. Significant 
difference was compared between M C group and M C + C A T group, and, D O X 
group and D O X + C A T group ( * p < 0.05, * * p < 0.005 ； n = 8 ) 
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3.4 Discussion 
Previous study showed that Mitomycin C (MC) enhanced superoxide and 
hydrogen peroxide formation in cardiac sarcosomes and required N A D P H as 
cofactor (Doroshow, 1981). This phenomenon was also observed in cardiac 
microsomes and perfused rat hearts using the Langendorff perfusion model in 
which superoxide dismutase (SOD), catalase, and iron-chelator ICRF-187 were 
capable of inhibiting the production of superoxide anion radical and hydroxyl 
radicals by M C (Politi et al” 1989). 
Doxorubicin was shown to produce hydroxyl radicals and superoxide 
radicals in perfused rat heart as well and this could be inhibited by co-
administration of iron-chelators, such as ICRF-187 (Pouna et al, 1995; Pouna et 
al, 1996). 
In our experiment, Langendorff perfusion of isolated rat hearts was used 
to observe the cardiotoxic effects of M C and D O X and to assess the 
V 
cardioprotection effect of natural antioxidant, (+)-Catechin. A m o n g the various 
parameters for assessing cardiac performance, w e made use of the Contraction 
Force, Heart Beat Rate and Flow Rate of the isolated perfused rat hearts. 
It was reported that such cardiotoxic effect of D O X and M C could be 
reduced and prevented by co-treatment with Probucol (a lipid-lowering drug 
with strong antioxidant properties),' Deferoxamine (an iron chelator) and 
T E M P O L (a member of piperidine nitroxide) in model of isolated perfused rat 
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hearts or in vivo (Siveski-Iliskovic et al, 1995; Hershko et al, 1996; Monti et al, 
1996). Our data showed that concomitant perfusion of (+)-Catechin with D O X or 
M C could reduce the cardiotoxic effects of these two drugs by restoring the 
cardiac performance near to the initial levels, though this restoration was not 
complete. It might protect the perfused rat hearts by binding and stabilising the 
free radicals (i.e. hydroxyl radicals, superoxide radicals) produced from D O X or 
M C by the rat hearts. It was suggested that dose optimisation of (+)-Catechin 
was essential to provide complete protection against the cardiotoxic effects of 
D O X or M C 
Nevertheless, w e suggest that Langendorff perfused isolated rat heart 
model could be used for fast screening and assessing of the cardiotoxic effect of 
clinically used antitumor drugs, such as D O X and M C , and the protective effect 
of cardioprotective agents, such as antioxidants. Also, (+)-Catechin could be 
applied in clinical trials accompanied with chemotherapy of D O X or M C in 
patients so as to reduce their adverse side effects in the hearts of patients. Our 
� . -
findings thus suggest the possibility of combined therapy and use of natural 
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CHAPTER FOUR THE EFFECT OF ANTIOXIDANTS DURING 
CHEMOTHERAPY OF DOXORUBICIN OR 
MITOMYCIN C IN TUMOR-BEARING MICE 
4.1 Introduction 
Tumor-bearing mice were used in present study as an animal model 
for assessing the cardioprotective of the antioxidants in combination with 
D O X or M C chemotherapy. This model mimicked the real clinical cancer 
chemotherapy situation. Both outbred mice, ICR, and inbred mice, BALB/c' 
were used in this research. The ranges of body weights of ICR and BALB/c 
were 30-38 g and 20-25 g, respectively. Mouse-specific tumors, Ehrlich ascites 
tumor (EAT) cells, were inoculated in their peritoneal cavity. A seven-day 
course of treatment was introduced to study the acute adverse side effect of 
these two drugs and either D Q X or M C was injected to the mice on three 
consecutive days during the course. At the end of the course, all mice were 
sacrificed and their hearts were collected for histological study and measuring 
the degree of lipid peroxidation in their hearts so as to evaluate the 
cardioprotective effects (results will be presented in Chapter 5) of the 
antioxidants on D O X or M C , respectively. The effect of these antioxidants on 
w 
the cytotoxic effect of both D O X or M C on EAT cells were evaluated by 
measuring relative viability of the EAT cells from the peritoneal cavity of the 
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mice at the end of the treatment period and the results will be reported 
herewith. 
Moreover, the effect of these antioxidants in the survival of EAT-
bearing mice was investigated. The EAT-bearing mice were treated with D O X 
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4.2 Materials and Methods 
Animals and tumor inoculation 
Protocol relating to animal studies in this thesis has obtained the approval 
of the Animal Research Ethics Committee, The Chinese University of Hong 
Kong. Adult BALB/c mice from the Animal House of the Chinese University of 
Hong Kong were used. They were fed on a stock laboratory diet (PICOLAB) and 
kept on a 12 h-light/12 h-dark cycle. Ehrlich ascites tumor cells (ATCC) were 
inoculated (1x106 cells per mouse) intraperitoneally. All injected mice developed 
an ascites tumor. 
Drugs administration 
D O X (Sigma), M C (Sigma), (+)-Catechin (Sigma) and N-Propyl gallate 
(Sigma) were dissolved in sterile PBS. The amount of drugs were D O X : 8mg/kg; 
M C : 4mg/kg; (+)-Catechin and N-Propyl gallate : 40mg/kg. For D O X treatment, 
•V-
intraperitoneal and intravenous injections were both used but in different groups 
of mice. The drugs were only administered on the day after the inoculation of 
E A T cells and continued on 3 consecutive days. Only PBS was injected into the 
control group in the same way of the drug-treated groups. 
r 
Isolation and measuremen ofviability oftumor cells 
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At the end of treatment, i.e. day seven, all the mice were sacrificed by 
cervical dislocation. The E A T cells were removed from the peritoneal cavity of 
the mice and washed and re-suspended in ice-cold PBS. The cell number of E A T 
cells were measured by the M T T Assay. M T T (Sigma) was dissolved 5mg/ml in 
ice-cold PBS just prior to use. A 20-fold dilution of E A T cells was made before 
adding M T T . For 1ml of E A T cells in PBS, 0.3ml of M T T solution was added. 
Then they were incubated at 37^C for 1 hour. For each sample, 0.5ml acidified 
(0.04 N HC1) 10% SDS was added and was incubated for 30 minutes. Then 1ml 
acidified isopropanol (0.04 N HC1 in isopropanol) was added and after 15 
minutes incubation, O.D.s4o was taken. The absorbance was converted to E A T 
cell per ml from a standard curve of absorbance against E A T cell number. The 
standard curve was prepared by using the same M T T assay and a serial of 
known cell densities of E A T cells suspended in ice-cold PBS. 
Effect ofantioxidants in the survival ofEAT-bearim mice 
Adult BALB/c mice from the Animal House of the Chinese University of 
Hong Kong were used. They were fed on a stock laboratory diet (PICOLAB) and 
kept on a 12 h-light/12 h-dark cycle. Ehrlich ascites tumor cells (ATCC) were 
inoculated (3x10? cells per mouse) intraperitoneally. All injected mice developed 
an ascites tumor. 
The EAT-bearing mice received intraperitoneal injection of D O X , M C , (+)-
Catechin, and N-propyl gallate in a 16-day course. Injection was given on every 
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3-day interval. They were given totally five injections during the course of 
treatment. At the end of the course, all the mice in the control group were dead 
hence the experiment was finished. The schedule of injection and dosage of 
drugs and antioxidants were shown as follows : 
Treatment Drug dosage Number of 
DOX MC NPG CAT injections Duratio 
n 
s s = ^ = s = s = s = ^ = = : I = ^ ^ ^ = ^ ^ ^ = ^ ^ = ^ ^ ^ = = ^ ^ = ^ ^ = = ^ = ^ = = ^ ^ ^ = ^ ^ = ^ ^ ^ = ^ ^ ^ ^ = ^ ^ ^ = ^ = 
DOX+NPG 2mg/kg - 20mg/kg - 5 16 days 
DOX+CAT 2mg/kg 一 - 20mg/kg 5 16 days 
DOX 2mg^g - - - 5 16 days 
NPG - - 20mg/kg - 5 16 days 
Con - - - - - 16 days 
CAT 一 - - 20mg/kg 5 16 days 
MC - 2mg/lcg - - 5 16 days 
V 
MC+NPG 一 2mg/kg 20mg/kg - 5 16 days 
MC+CAT - 2mg^g - 20mg/kg 5 16 days 
9 
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4.3 Results 
Effect of(+)-Catechin on the antitumor activity ofMC 
EAT-bearing BALB/c mice were injected with 3 doses of either 
Mitomycin C (MC) alone or Mitomycin C plus (+)-Catechin on 3 consecutive 
days. In the presence of (+)-Catechin, M C (4mg/kg) showed an average 2.5% 
of cytotoxicity on E A T cells in vivo (Figure 4.3.1). W e found that at the dose of 
40mg/kg, (+)-Catechin did not affect the cytotoxic effect of M C (4mg/kg) on 
E A T cells in vivo (Figure 4.3.1). Though (+)-Catechin reduced the cytotoxicity 
of M C on EAT-bearing mice from a mean value of E A T cell viability of 1% to 
2.5% (Figure 4.3.1), this was not statistically significant 
Our data suggest that this dose of M C (4mg/kg) was very effective in 
suppressing the growth of E A T cells in vivo by reducing the E A T cell viability 
to a very low percentage, i.e. below 3% (Figure 4.3.1) and (+)-Catechin at dose 
of 40mg/kg would not affect the cytotoxicity of M C on E A T cells in the 
\-
tumor-bearing mice. 
W e will monitor the probable cardioprotective effect of (+)-Catechin in 
MC-treated EAT-bearing mice under this treatment protocol by histological or 
biochemical studies (results will be presented in Chapter 5). 
0 
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Figure 4.3.1 Effect of (+)-Catechin on the antitumor activity of 
Mitmycin C (MC) on EAT in vivo. 
E A T cells (lxl06/mouse) in PBS were inoculated intraperitoneally onto 
BALB/c mice on Day Zero. O n Day One ,Three and Five, except control 
group, mice were treated with Mitomycin C (MC) and/or (+)-Catechin. 
Mitomycin C (4mg/kg) in water was injected i.p.. (+)-Catechin (40mg/kg) in 
water was injected i.p. just after injection of M C . O n Day Six, all mice were 
sacrificed and E A T cells were removed from the peritoneal cavity, washed 
and re-suspended in PBS. The cell viability of E A T cells was measured by 
M T T Assay. A standard curve of known E A T cell density was prepared at the 
same time and in the same reaction. Cell density of each group was obtained 
directly by referring the O.D.540 of each group to the standard curve. Vertical 
bar represented one standard error. ‘ 
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Effect of(+)-Catechin on the antitumor activitu ofDOX 
O n the other hand, if (+)-Catechin (40mg/kg) was injected with 
Doxorubicin (DOX, 8mg/kg) in EAT-bearing mice at the same treatment 
protocol, the cytotoxicity of D O X on E A T cells in vivo was enhanced (Figure 
4.3.2). W h e n EAT-bearing BALB/c mice were injected with D O X (8mg/kg) 
alone on 3 consecutive days, the average E A T cell viability was reduced to 7% 
(Figure 4.3.2) of the untreated group. If (+)-Catechin (40mg/kg) was injected 
at the same time of D O X , the average E A T cell viability was further reduced 
to less than 1% (Figure 4.3.2) of the untreated group. This dose of (+)-Catechin 
nearly gave a 7-fold of cytotoxicity enhancement of D O X on E A T cells in vivo. 
This result indicates that (+)-Catechin is specifically suitable to be used 
as a cardioprotective agent in DOX-treated host because (+)-Catechin can 
enhance the cytotoxicity of D O X on tumor cells in vivo. In Chapter Five, w e 
will make use of the above (+)-Catechin and D O X combined treatment 
protocol to investigate the probable cardioprotective effect of (+)-Catechin in 
V 
DOX-treated EAT-bearing mice. 
• 
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Figure 4.3.2 Effect of (+)-Catechin on the antitumor activity of 
Doxorubicin (DOX) on EAT in vivo. 
E A T cells (IxlO^/mouse) in PBS were inoculated intraperitoneally onto 
BALB/c mice on Day Zero. O n Day One ,Three and Five, except control 
group, mice were treated with Doxorubcin (DOX) and/or (+)-Catechin. 
Doxorubicin (8mg/kg) in water was injected i.p.. (+)-Catechin (40mg/kg) in 
water was injected i.p. just after injection of D O X . O n Day Six, all mice were 
sacrificed and E A T cells were removed from the peritoneal cavity, washed 
and re-suspended in PBS. The cell viability of E A T cells was measured by 
M T T Assay. A standard curve of known E A T cell density was prepared at the 
same time and in the same reaction. Cell density of each group was obtained 
directly by referring the O.D.540 of each group to the standard curve. Vertical 
bar represented one standard error. ‘ 
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Effect ofN'propyl gallate on the antitumor activitu ofMC 
In another species of mice, ICR strain, M C (4mg/kg) was injected 
either alone or combined with N P G (40mg/kg) on 3 consecutive days. W e 
found that M C alone reduced the average E A T cell viability in vivo to about 
90% (Figure 4.3.3) of the untreated group. However, when N P G was injected 
with M C , it reduced the average E A T cell viability in vivo to 50% (Figure 4.3.3) 
of the untreated group. This results shows that N P G in such dose could 
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Figure 4.3.3 Effect of N-Propylgallate (NPG) on the antitumor 
activity of Mitomycin C (MC) on EAT in vivo. 
E A T cells (lxl06/mouse) in PBS were inoculated intraperitoneally into ICR 
mice on Day Zero. O n Day One ,Three and Five, except control group, mice 
were treated with Mitomycin C (MC) and/or N-Propylgallate (NPG). 
Mitomycin C (4mg/kg) in water was injected i.v.. N-Propylgallate (40mg/kg) 
in water was injected i.v. just after injection of M C . O n Day Six, all mice were 
sacrificed and E A T cells were removed from the peritoneal cavity, washed 
and re-suspended in PBS. The cell viability of E A T cells was measured by 
M T T Assay. A standard curve of known EAT cell density was prepared at the 
same time and in the same reaction. Cell density of each group was obtained 
directly by referring the O.D.s40 of each group to the standard curve. Vertical 
bar represented one standard error. 
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Effect ofN-propyl gallate on the antitumor activity ofDOX 
In EAT-bearing BALB/c mice, D O X (8mg/kg) when injected alone on 3 
consecutive days reduced the average E A T cell viability to 80% (Figure 4.3.4) 
of the untreated group. If N P G (40mg/kg) was injected at the same time of 
D O X , it did not either enhance or reduce the antitumor effect of D O X on E A T 
cells in vivo (Figure 4.3.4). The difference between antitumor activity of D O X 
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Figure 4.3.4 Effect of N-Propylgallate (NPG) on the antitumor 
activity of Doxorubicin (DOX) on E A T in vivo. 
E A T cells (lxl06/mouse) in PBS were inoculated intraperitoneally onto 
BALB/c mice on Day Zero. O n Day One ,Three and Five, except control 
group, mice were treated with Doxorubcin (DOX) and/or N-Propylgallate 
(NPG). Doxorubicin (8mg/kg) in water was injected i.v.. N-Propylgallate 
(40mg/kg) in water was injected i.v. just after injection of D O X . O n Day Six, 
all mice were sacrificed and EAT cells were removed from the peritoneal 
cavity, washed and re-suspended in PBS. The cell viability of E A T cells was 
measured by M T T Assay. A standard curve of known EAT cell density was 
prepared at the same time and in the same reaction. Cell density of each 
group was obtained directly by referring the O.D.540 of each group to the 
standard curve. Vertical bar represented one standard error. 
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Effect ofantioxidants in the survival ofEAT-bearing mice 
The survival of (+)-Catechin (CAT) treated group and Mitomycin C 
(MC) treated group were 10% and 36% (Figure 4.3.5) respectively. If C A T and 
M C were injected concomitantly, the survival of the MC+CAT-treated group 
was 57% (Figure 4.3.5) which was greater than that of the CAT-treated or the 
MC-treated groups. The survival of N-Propyl gallate (NPG) treated group 
was 0% which was the same of the control group. If N P G and M C were 
injected concomitantly, the survival of the MC+NPG-treated was 50% (Figure 
4.3.5) which was greater than that of the NPG-treated or the MC-treated 
groups. 
As a result, C A T alone could prolong the survival of EAT-bearing 
mice. If it was given with M C , the survival was much greater than either C A T 
alone or M C alone. It could prolong survival of the MC-treated EAT-bearing 
mice. O n the other hand, N P G had the same effect on MC-treated EAT-
bearing mice. It prolonged the survival of MC-treated EAT-bearing mice if it 
,> • 
was given simultaneously with M C 
The survival of Doxorubicin (DOX) treated group was 95% (Figure 
4.3.5) which was greater than that of the control group. The survival of 
DOX+NPG-treated and DOX+CAT-treated groups both were 95% (Figure 
4.3.5). This was much greater than that of the control group and the CAT-
treated and the NPG-treated groups.‘ 
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Figure 4.3.5 Effect of combined treatment of N-Propyl gallate (NPG) 
and (+)-Catechin (CAT) ，and Doxorubicin (DOX) or 
Mitomycin C (MC) on the survival of EAT-bearing 
mice. 
In a 16-day treatment, E A T (lxlO^ cells/mouse) was inoculated into the 
peritoneal cavity of BALB/c mice on D A Y 0. There were 15 mice in each 
group. Beginning on D A Y 1, mice except those in control group were give 
injections of antitmor drug alone or antitumor drug and antioxidant on every 
3-day till D A Y 13. D O X and M C were given 2mg/kg whilst N P G and C A T 
were given 20mg/kg. In the groups of combined treatment, antioxidants were 
injected concomitantly with antitumor drug. O n D A Y 15, all the mice in the 
control group were dead. All the deaths were recorded as well. 
4k 
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4.4 Discussion 
Doxorubicin (DOX) and Mitomycin C (MC) represent two of the 
prevailing antineoplastic drugs which are found to be very effective in a variety 
of soft and solid human malignancies. However it became obvious that they have 
the very serious side effects which is believed to be caused by their free radical 
generation effect during biotransformation in the host under aerobic activation 
(Gille and Nohl, 1997; Nishiyama et al” 1997). Organs which have no or less 
antioxidant defence system could not withstand this oxidative stress, causing 
tissue damage and organ malfunction. Heart, having very little defence ability, is 
the most susceptible organ to be damage by D O X and M C (Rajagopalan et al, 
1988; Pritsos and Briggs, 1 9 9 6 ) . 
Dose reduction is one of the ways to reduce the side effects but the 
efficacy of antitumor is also lowered. Various means are used to attenuate the 
free radical attacks. Transition metal chelators which gave promising in vitro and 
V 
in vivo results were found to be fail in clinical trials (Herman et al, 1997). It was 
under investigation that natural compounds from plants can be used instead of 
chemoprotective agents (Monti et aL, 1996). In view of this, w e suggest herewith 
to test the effect of natural antioxidants which are non-toxic to the host. 
However, before these antioxidants can be used in combined treatment with 
D O X or M C , w e have to prove that these antioxidants will not interfere the 
cytotoxic effect of D O X or M C on tumor cells. 
秦 
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In an EAT-bearing mice model, in BALB/c or ICR mice, (+)-Catechin did 
not interfere but enhanced the tumor cytotoxic effect of D O X on E A T cells in vivo 
(Figure 4.3.2). In another experiment, (+)-Catechin did not either interfere or 
enhance the antitumor activity of M C on E A T cells in vivo (Figure 4.3.1). N-
Propyl gallate, on the other hand, enhanced the antitumor effect of M C on E A T 
cells in vivo (Figure 4.3.3) but it did not either interfere or enhance the antitumor 
effect of D O X on E A T cells in vivo (Figure 4.3.4). The reasons for differentiation of 
in vivo antitumor effects of these two antioxidants needed to be further studied. 
In Chapter Two, w e have demonstrated the cytotoxicity of (+)-Catechin or 
N-propyl gallate on human hepatoma cells in vitro. The result in EAT-bearing 
mice in this chapter further prove that these antioxidants can be applied in 
combination with D O X or M C for treating tumors. The underlying mechanism 
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CHAPTER FIVE HISTOLOGICAL STUDY AND LIPID 
PEROXIDATION STUDY OF PROTECHVE 
EFFECT OF ANTIOXIDANTS IN TUMOR-
BEARING MICE TREATED WITH DOXORUBICIN 
OR MITOMYCIN C 
5.1 Introduction 
In the investigation of the adverse side effects of Doxorubicin (DOX) or 
Mitomycin C (MC), biochemical assays provide information about the nature 
and mechanism of reactions leading to these side effects. O n the other hand, 
histological study of organs or tissues from host which received treatment of 
D O X or M C , give parameters that can locate the target site of these side effects. 
By this information, one can pinpoint the sites of damage. Further more, by the 
biochemical basis of these side effects, one can understand the mechanism and 
develop the strategies or application of protective agents to reduce or recover the 
damage. 
Doxorubicin and Mitomycin C are two commonly used anticancer 
quinones. Their free radicals releasing activity after cellular biotransformation is 
well documented and the free radicals are known to cause adverse side effects to 
the host. The damage extend from liver, kidney to the most susceptible organ, 
namely the heart. As mitochondria are the sites of phosphorylation and electron 
m> 
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transport, it is believed that they are most susceptible to the attack of these 
anticancer quinones (Lee et al, 1991). Other subcellular compartments include 
endoplasmic reticulum (ER), sacroplasmic reticulum, etc. As they are enclosed by 
lipid bilayers, the unsaturated fatty acid portion of the membranes will undergo 
the free radicals attack too, causing irreversible damage to the cells and hence the 
organ. 
In this research, w e made use of the treatment protocols in Chapter 4 to 
study the cardiac protective effect of antioxidants. Tumor-bearing mice were 
obtained by prior inoculation of Ehrlich ascites tumor (EAT) cells in the 
peritoneal cavities of BALB/c mice. They were then treated with D O X with or 
without antioxidant on 3 consecutive days. These protocols have been 
demonstrated in Chapter 4 to be effective in killing E A T cells in vivo. At the end 
of treatment, the mice were sacrificed and their hearts were removed for 
histological observation under light microscope. The organisation of the 
myocardial filaments and the formation of vacuolisation were monitored. 
W e also studied the mechanism of the probable cardioprotective effect of 
antioxidants on the DOX- or MC-treated EAT-bearing mice by estimating the 
degree of lipid peroxidation of hearts after treatments. It is known that free 
radicals can cause destruction of nearby macromolecules due to their extremely 
high reactive unpaired electrons. These adverse effects include lipid 
peroxidation, protein oxidation, D N A fragmentation, etc. Thus, by measuring 
the intermediates or metabolites of the destruction of these macromolecules, one 
• 
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can estimate the extent of free radicals-related destruction. As most proteins can 
be turned over and recovered from the expression of the D N A , lipid 
peroxidation is considered as a more severe, irreversible and permanent damage. 
The polyunsaturated fatty acids are particularly susceptible to peroxidation and 
that once initiated, the process proceeds as a free radical chain reaction. The 
occurrence of lipid peroxidation in biological membranes causes impairment of 
membrane functioning, decreased fluidity, inactivation of membrane-bound 
receptors and enzymes and increased non-specific permeability to ions, such as 
Ca2+ and etc. (Gutteridge and Halliwell, 1990). 
In this research, thiobarbituric acid assay (TBA) assay was used as a single 
assay for measuring the end products of the lipid peroxidation in the hearts of 
the tumor-bearing mice which were treated with Doxorubicin and Mitomycin C 
prior to the assay. The end product of lipid peroxidation in heart is an aldehyde 
called, Malondialdehyde (MDA). One M D A molecule reacts with two molecules 
of T B A in an acidic and hot condition to form a chromogen which can be 
V 
measured at or close to 532nm. 
• 
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5.2 Materials and Methods 
Animals 
Adult BALB/c mice from the Animal House of The Chinese University of 
Hong Kong were used. They were fed on a stock laboratory diet (PICOLAB) and 
kept on a 12 h-light/12 h-dark cycle. Ehrlich ascites tumor cells (ATCC) were 
inoculated (lxlO^ cells per mouse) intraperitoneally. All injected mice developed 
an ascites tumor. 
Drugs administration 
The treatment protocols as described in Chapter 4 were used. These 
protocols have been demonstrated to provide antitumor effects in EAT-bearing 
mice. 
D O X (Sigma), M C (Sigma), and N-Propyl gallate (Sigma) were dissolved 
V 
in sterile PBS. The amount of drugs were D O X : 8mg/kg; M C : 4mg/kg; and N-
Propyl gallate : 40mg/kg. For the treatments, intraperitoneal injections were 
used in different groups of mice. The drugs were only administered on the day 
after the inoculation of EAT cells and continued on 3 consecutive days. Only PBS 
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Tissue preparation procedurefor light microscope (LM) 
The mice were sacrificed by cervical dislocation on the day after the last 
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Procedures Reagents Time 
Fixing Bouin's Fluid or 10% buffered formalin about 24 hr. 
Processing Dehydrating • 
• 
50% Ethanol 1 hr. 
70% Ethanol 1 hr. 
85% Ethanol 1 hr. 
95% Ethanol 1 hr. 
100% Ethanol 1 hr. 
100% Ethanol 1 hr. 
100% Ethanol 2 hr. 
Clearing: 
Xylene : Ethanol (1:1) 1 hr. 
Xylene 1 hr. 
Xylene 1 hr. 
Infiltration: 
Paraffin wax 1 hr. 
Paraffin wax 1 hr. 
Paraffin wax 2 hr. 
(vacuum aspiration if needed) 
Embedding: 
Paraffin wax 
(allow to cool and trim) 
Sectioning Section at 7 m m thick, adhere on slides by egg 
albumin and dry on warm plate or oven 
overnight. 
Staining Dewax: 
Xylene 5 min. 
Xylene 5 min. 
Hydration: 
100% Ethanol 1 min. 
95% Ethanol 1 min. 
70% Ethanol 1 min. 
50% Ethanol 1 min. 
30% Ethanol 1 min. 
running tap water 1 min. 
« 
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Staining: 
Mayer's Hematoxylin 15 min. 
Tap water 1 min. 
1 % acidified alcohol 2 sec. 
Tap water 1 min. 
Scott's tap water 1 min. 
Tap water 1 min. 
0.5% aqueous Eosin 1 min. 
Tap water 1 min. 
Dehydrating • 
• 
70% Ethanol 1 min. 
95% Ethanol 1 min. 
100% Ethanol 2 min. 
100% Ethanol 2 min. 
Xylene : Ethanol (1:1) 2 min. 
Xylene 2 min. 
Xylene 2 min. 
Mounting: 
Canada Balsam 
The sections were observed under light microscope (OLYMPUS) by 
different combination of magnification values of the eye pieces and objective lens 
of the microscope. Pictures of the heart sections under microscope were taken for 
record and comparison. 、 
Lipid peroxidation assay 
The method of Nowak et al. (1995) was followed with minor 
modifications. Mice in treated and untreated groups were sacrificed by cervical 
dislocation and hearts were quickly removed for the For 125mg portions of wet 
hearts were homogenised on ice with 1ml of 1.15% KC1 and mixed with 2ml of 
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0.25 N HC1 containing 0.375% wt/vol thiobarbituric acid, 15% wt/vol 
trichloroacetic acid, and 0.015% wt/vol butylated hydroxytoluene. After 
incubation at 1000C for 20 minutes, samples were centrifuged (3000 X g for 15 
minutes) and the absorbance of the supernatant was measured against a blank 
containing 1.15% KC1 instead of organ homogenate at 532nm. A n extinction 
coefficient of 1.56 x 10^ M_icm_i was used to calculate micromoles of M D A per 
gram of wet heart. 
Expression ofresults and statistical significance 
The results were expressed as means 土 S.D. The statistical significance of 
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5.3 Results 
Heart sections ofuntreated EAT-bearing mice 
From Figures 5.3.1 to 5.3.3, heart sections of mice were observed under 
three different combinations of magnification preparations. They belonged to the 
control group in which no Doxorubicin (DOX) or N-propyl gallate (NPG) was 
injected to the mice. In these sections of control group, the pattern of myocardial 
muscle alignment and the location of muscle cell nuclei could be observed. W e 
found that under normal conditions, the myocardial filaments were well-
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F i g u r e 5 . 3 . 1 E A T - b e a r i n g m o u s e h e a r t s e c t i o n ( c o n t r o l g r o u p )• 
Magnification : 2.5 x 40 x 2 ； 
Sample : ventricular wall portion ； 
Ehrlich ascites tumor (lxlO^ cells/per mouse) was inoculated intraperitoneally 
into BALB/c mice. D O X (8mg/kg) and N P G (40mg/kg) were injected 
intraperitoneally into EAT-bearing mice 24 hr. after EAT inoculation and the 
injection was continued on the following 3 consecutive days. Twenty four hours 
after the last D O X injection, the mice were sacrificed by cervical dislocation and 
the hearts were quickly removed. After fixation and staining, the hearts samples 
were observed under light microscope and pictures were taken for record. 
hi control group, no D O X or N P G were injected. 
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Figure 5.3.2 EAT-bearing mouse heart section ( control group )• 
Magnification : 2.5 x 20 x 1.25 ； 
Sample : ventricular wall portion ； 
Ehrlich ascites tumor (1x106 cells/per mouse) was inoculated intraperitoneally 
into BALB/c mice. D O X (8mg/kg) and N P G (40mg/kg) were injected 
intraperitoneally into EAT-bearing mice 24 hr. after EAT inoculation and the 
injection was continued on the following 3 consecutive days. Twenty four hours 
after the last D O X injection, the mice were sacrificed by cervical dislocation and 
the hearts were quickly removed. After fixation and staining, the hearts samples 
were observed under Ught microscope and pictures were taken for record. 
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Figure 5.3.3 EAT-bearing mouse heart section (control group )• 
Magnification : 2.5 x 4 x 2 ； 
Sample : ventricular wall portion ； 
Ehrlich ascites tumor (lxlO^ cells/per mouse) was inoculated intraperitoneally 
into BALB/c mice. D O X (8mg/kg) and N P G (40mg/kg) were injected 
intraperitoneally into EAT-bearing mice 24 hr. after E A T inoculation and the 
injection was continued on the following 3 consecutive days. Twenty four hours 
after the last D O X injection, the mice were sacrificed by cervical dislocation and 
the hearts were quickly removed. After fixation and staining, the hearts samples 
were observed under light microscope and pictures were taken for record. 
In control group, no D O X or N P G were injected. 
» 
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Heart sections ofDOX-treated EAT-bearing mice 
From Figures 5.3.4 to 5.3.6, the heart sections of mice were also observed 
under three different combinations of magnification power. They belonged to the 
D O X group in which the mice were injected with Doxorubicin (DOX) only. In 
these figures, w e found that the organization of myocardial filament was 
disrupted by D O X and vacuolization was found, compared with that of the 
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Figure 5.3.4 EAT-bearing mouse heart section ( DOX group )• 
Magnification : 2.5 x 40 x 1.25 ； 
Sample : ventricular wall portion ； 
Ehrlich ascites tumor (lxlO^ cells/per mouse) was inoculated intraperitoneally 
into BALB/c mice. D O X (8mg/kg) was injected intraperitoneally into EAT-
bearing mice 24 hr. after E A T inoculation and the injection was continued on the 
following 3 consecutive days. Twenty four hours after the last D O X injection' the 
mice were sacrificed by cervical dislocation and the hearts were quickly 
removed. After fixation and staining, the hearts samples were observed under 
light microscope and pictures were taken for record. 
In D O X group, only D O X was injected. 
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Figure 5.3.5 EAT-bearing mouse heart section ( DOX group )• 
Magnification: 2.5 x 20 x 1.6 ； 
Sample : ventricular wall portion ； 
Ehrlich ascites tumor (1x106 cells/per mouse) was inoculated intraperitoneally 
into BALB/c mice. D O X (8mg/kg) was injected intraperitoneally into EAT-
bearing mice 24 hr. after E A T inoculation and the injection was continued on the 
following 3 consecutive days. Twenty four hours after the last D O X injection, the 
mice were sacrificed by cervical dislocation and the hearts were quickly 
removed. After fixation and staining, the hearts samples were observed under 
light microscope and pictures were taken for record. 
In D O X group, only D O X was injected. 
0 
109 
Histological study and Biochemical study ^ * . 
M 
Figure 5.3.6 EAT-bearing mouse heart section ( DOX group )• 
Magnification: 2.5 x 4 x 2 ； 
Sample : ventricular wall portion ； 
Ehrlich ascites tumor (lxlO^ cells/per mouse) was inoculated intraperitoneally 
into BALB/c mice. D O X (8mg/kg) was injected intraperitoneally into EAT-
bearing mice 24 hr. after E A T inoculation and the injection was continued on the 
following 3 consecutive days. Twenty four hours after the last D O X injection, the 
mice were sacrificed by cervical dislocation and the hearts were quickly 
removed. After fixation and staining, the hearts samples were observed under 
light microscope and pictures were taken for record. 





Histological study and Biochemical study 
^ 
Heart sections of DOX+NPG-treated EAT-hearim mice 
From Figures 5.3.7 to 5.3.9, the heart sections of mice were also observed 
under three different combinations of magnification power. They belonged to the 
D O X + N P G group in which the mice were injected with Doxorubicin (DOX) and 
N-propyl gallate concomitantly. In these figures, w e found that the disruption of 
myocardial filaments and vacuolization formation were partially inhibited and 
reduced by the presence of N P G , compared to that of the DOX-treated group 
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Figure 5.3.7 EAT-bearing mouse heart section ( D O X + N P G group). 
Magnification : 2.5 x 40 x 1.6 ； 
Sample : ventricular wall portion ； 
Ehrlich ascites tumor (1x106 cells/per mouse) was inoculated intraperitoneally 
into BALB/c mice. D O X (8mg/kg) and N P G (40mg/kg) were injected 
intraperitoneally into EAT-bearing mice 24 hr. after EAT inoculation and the 
injection was continued on the following 3 consecutive days. Twenty four hours 
after the last D O X injection, the mice were sacrificed by cervical dislocation and 
the hearts were quickly removed. After fixation and staining, the hearts samples 
were observed under light microscope and pictures were taken for record. 
In D O X + N P G group, both D O X and N P G were injected. 
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Figure 5.3.8 EAT-bearing mouse heart section ( D O X + N P G group )• 
Magnification : 2.5 x 20 x 1.6 ； 
Sample : ventricular wall portion ； 
Ehrlich ascites tumor (1x106 cells/per mouse) was inoculated intraperitoneally 
into BALB/c mice. D O X (8mg/kg) and N P G (40mg/kg) were injected 
intraperitoneally into EAT-bearing mice 24 hr. after E A T inoculation and the 
injection was continued on the following 3 consecutive days. 24 hr. after the last 
D O X injection, the mice were sacrificed by cervical dislocation and the hearts 
were quickly removed. After fixation and staining, the hearts samples were 
observed under light microscope and pictures were taken for record. 
In D O X + N P G group, both D O X and N P G were injected. 
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Figure 5.3.9 EAT-bearing mouse heart section ( D O X + N P G group ). 
Magnification : 2.5 x 4 x 1.6 ； 
Sample : ventricular wall portion ； 
Ehrlich ascites tumor (1x106 cells/per mouse) was inoculated intraperitoneally 
into BALB/c mice. D O X (8mg/kg) and N P G (40mg/kg) were injected 
intraperitoneally into EAT-bearing mice 24 hr. after EAT inoculation and the 
injection was continued on the following 3 consecutive days. Twenty four hours 
after the last D O X injection, the mice were sacrificed by cervical dislocation and 
the hearts were quickly removed. After fixation and staining, the hearts samples 
were observed under light microscope and pictures were taken for record. 
In D O X + N P G group, both D O X and N P G were injected. 
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Effect ofDOX and MC in the lipid peroxidation ofhearts ofEAT-hearim mice 
Injecting the same doses of D O X (8mg/kg) and M C (4mg/kg) and giving 
the same frequency (3 consecutive days) of injection, D O X and M C increased 
lipid peroxidation (Figure 5.3.10) in hearts of EAT-bearing BALB/c mice, as 
measured by thiobarbituric acid assay (TBA) for the production of 
malonedialdehyde (MDA). 
By a dose of 40mg per kg and injected on 3 consecutive days 
concomitantly with D O X , N-propyl gallate (NPG) could not inhibit and reduce 
the lipid peroxidation in hearts of mice (Figure 5.3.10) as measured by the TBA-
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Figure 5.3.10 Doxorubicin (DOX) anchor Mitomycin C (MC) induced-
lipid peroxidation in mice heart. 
E A T cells (lxl06/mouse) were inoculated intraperitoneally into BALB/c mice on 
Day Zero. O n Day One, Three and Five, Doxorubicin (8mg/kg) and/or 
Mitomycin C (4mg/kg) were injected i.p. into all mice except control group. In 
D O X + N P G group, N-Propyl gallate (NPG, 40mg/kg) was injected i.p. just after 
D O X injection. O n Day Six, all mice were sacrificed and their hearts were 
removed and homogenized in 1.15% KC1. Then 0.25N HC1 containing 0.375% 
wt/vol. thiobarbituric acid, 15% wt/vol trichloroacetic acid and 0.015% wt/vol 
butylated hydroxytoluene were added and all mixtures were incubated at 100^0 
for 20 minutes. After that/all samples were centrifuged (3000Xg for 5 minutes) 
and the absorbance of the supernatant was measured against a blank containing 
1.15% KC1 instead of heart homogenate at 532nm. A n extinction coefficient of 
1.56x105 M-^cm-i was used to calculate micromoles (^imol) of M D A per gram of 
wet heart. (This assay was modified from Nowak et al., 1995). Vertical bar 
represented one standard error. The difference between treatment groups and 
control group was determined by the Student's t-test. (* p < 0.01) 
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5.4 Discussion 
It was established that Doxorubicin would develop cardiomyopathy and 
congestive heart failure in patients (Siveski-Iliskovic et al, 1995). In this 
experiment, w e have demonstrated that Doxorubicin could cause cardiac toxicity 
in hearts of mice. This phenomenon could be found in the myocardial cell 
damages; and observed under light microscope by preparing and staining the 
heart sections of the mice. In the DOX-treated group, w e observed vacuolisation, 
dilation and disruption of myofibrils arrangement in the heart sections of mice, 
compared to the control group. Since it was commonly recognised that DOX-
induced cardiac damage was due to free radical production of D O X (Luo et al, 
1997), naturally occurring antioxidant was used in this experiment accompanied 
with D O X treatment so as to reduce the free radicals generated in the cytotoxic 
action of D O X . N-Propyl gallate was used in this experiment and injected 
concurrently with D O X into the mice. 
N-Propyl gallate is belonged to the family of alkyl gallate and is well-
known for its antioxidant activities. It was found to intensively inhibit fatty acid 
desaturation in fungus and rat liver microsomes (Kawashima et al, 1996). W h e n 
N-Propyl gallate was injected at the same time of D O X , the degree of myocardial 
cell damages was lowered (Figures 5.3.7 to 5.3.9). Though the disruption of 
myofibrils was not completely prevented, this result suggests the possibility that 
the adverse effect of D O X was due to free radical production and this toxic effect 
« 
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could be prevented and reduced by concurrent treatment of antioxidants, such as 
N-Propyl gallate. Also, in a previous experiment (Chapter 4), w e have already 
demonstrated that at a dose of 40mg/kg, N-Propyl gallate did not affect the 
cytotoxic effect of D O X (8mg/kg) on E A T cells in vivo. Moreover, since the EAT-
bearing mice have received three doses of D O X and N-Propyl gallate, thus 
repetitive injection of N-Propyl gallate in this experiment was not toxic to the 
host. In spite of this, w e needed to optimise the dose of N-Propyl gallate so that it 
could provide its greatest protective effect against the free radical damages of 
D O X in heart, but at the same time, without affecting the antitumor cytotoxic 
effect ofDOX. 
The acute effect of D O X was evaluated in this experiment as the time 
course was seven days. Since N-Propyl gallate itself does not cause toxicity to the 
mice, it is possible that in clinical situation, patients may be pretreated or co-
treated with N-Propyl gallate at the time of D O X chemotherapy. Our results 
suggest that it is possible to minimise the acute side effect of D O X in hearts by N-
� -
Propyl gallate administration. 
N-Propyl gallate is a naturally occurring antioxidant from plants and one 
of the components commonly used to preserve foods. It was shown to protect the 
isolated rat heart from reperfusion injury (Bhatnagar, 1993). It is capable of 
accepting unpaired electrons in free radical species, such as hydroxyl or 
superoxide radicals. W e propose that N-Propyl gallate in this experiment 
reduced the cardiac toxicity of D O X by stabilising the free radical species 
« 
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released during the drug actions of D O X , and thus terminating the propagation 
of free radical reaction. Our results suggest the potential use of natural 
antioxidants in plants in the protection of patients in chemotherapy so that the 
dose of chemotherapy agents need not be reduced because of their adverse side 
effects. 
As described in previous Chapter 2, N-Propyl gallate could elevate the 
defence system of the endothelial cells by inducing the expression of free radical 
scavenging enzyme Mn-SOD. In this chapter, w e used the thiobarbituric acid 
(TBA) assay to estimate the amount of malonedialdehyde (MDA) formed in the 
heart, which is the metabolite of lipid peroxidation. T w o T B A molecules reacted 
with one molecule of M D A to form a chromogen (Di Pierro et al, 1992). Our data 
showed that in short course of 7-day treatment, repetitive injection of D O X or 
M C caused lipid peroxidation in the hearts of EAT-bearing mice (Figure 5.3.10). 
However, the protective effect of either N-Propyl gallate or (+)-Catechin 
in the hosts' hearts by M D A estimation was not obvious. This may be due to the 
V 
lipid in the heart cell is not the major damaged sites. It is also probable because of 
the low sensitivity of the TBA assay. It was suggested that as M D A is not 
necessarily the primary and direct lipid peroxidation product of exogenous or 
endogenous reactive oxygen species, it is not an ideal indirect measure for low-
to-medium-levels of oxygen free radicals (Ballagi-Pordany et al, 1991). The 
unstability of M D A may also lower the sensitivity of the T B A assay if the sample 
size was great. Though peroxidation of protein is suggested as an alternative 
« 
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method, but the turnover rate of proteins and its role as a functional copy of 
genes make it unsuitable for indicating the exact amount of free radical-induced 
peroxidation. As a result, T B A assay was suggested to be used as a general or 
macro method for preliminary assessment of the peroxidation of the sample and 
was used in experiments in this Chapter. Other parameters, such as the activity 
and level of expression of endogenous antioxidant enzymes, glutathione 
reductase, glutathione S-transferase, glutathione peroxidase, Mn-SOD, etc. in the 
hearts in these treated mice will be investigated in future studies. 
The timing of injection of antioxidants into the host also affected the 
efficacy of the antioxidants against the oxidants. However, this was not exclusive 
at all. Pre-treatment or concomitant treatment was introduced because the host 
was well equipped with plenty of antioxidants to deal with the burst of free 
radicals generated from the biotransformation of D O X and M C (Monti et al., 
1996). This was important that the free radical damage of D O X and M C on host 
was irreversible and cumulative (Doroshow, 1981; Olson and Mushlin, 1990). The 
•V 
antioxidants in our research were injected concomitantly with D O X or M C so as 
to capture the free radicals as soon as possible at the time they were formed and 
induced. By this antioxidant co-treatment, it would be possible that the dose of 
D O X and M C needed not to be reduced for their cumulative effects in patients 
,and the time of chemotherapy could be lengthened too, whilst the patients were 
protected from the free radical side effects of D O X and M C . They could then 
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withstand the chemotherapy for the reason that their vital organs or tissues were 
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Effect ofexogenous ATP on DOX- orMC-treated HepG2 
CHAPTER SIX EFFECT OF EXOGENOUS ATP ON THE ANTITUMOR 
ACTIVITY OF DOXORUBICIN AND MITOMYCIN C ON 
CULTURED HUMAN HEPATOMA CELLS 
6.1 Introduction 
In cancer chemotherapy, the severe toxicity of the antitumor drugs to the 
patients raise the outcry that whether w e can discriminate the malignant tissues 
from the normal tissues. In case w e can successfully distinguish the tumor tissues 
from the normal tissues, w e can target the antitumor drugs only onto the tumors 
avoiding the adverse side effects on the normal tissues. This has been the 
controversial topic in cancer research. O n the other hand, if w e can selectively 
suppress the growth or metabolism of tumor cells rather than the normal cells, to 
certain extent, w e can discriminate the tumors from the normal tissues. In such a 
way, w e can use lower doses of antitumor drugs to reach the same cytotoxic 
V 
effect and can somehow lower the adverse side effects of these antitumor drugs. 
Glutathione (GSH) in its reduced form and its related metabolic enzymes, 
are well recognised as one of the essential cellular defence systems against 
oxidative stress, and one of the supplies of peptides and reducing power (Mistry 
and Harrap, 1991). It also plays an important role in the mechanisms of 
multidrug resistance of many tumor cells. Research showed that tumor cells, 
which have relatively high level of intracellular G S H or are capable of 
« 
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maintaining cellular G S H level, were more resistant or highly resistant to 
chemotherapy (Doroshow et al., 1990). It was then suggested that if one can 
interfere the metabolism of intracellular G S H by lowering its levels in tumor 
cells, one may enhance the efficacy of antitumor drugs by reducing the resistance 
from tumors. C o m m o n G S H reducing agents including buthionine sulfoximine 
(BSO) or diethyl maleate (DEM), showed great ability in suppressing the 
intracellular G S H both in vitro and in vivo (Terradez et al, 1993; and Estrela et al, 
1995). However, these G S H suppressing agents cannot discriminate tumor cells 
from normal cells and therefore they also suppress the G S H in normal tissues. In 
view of this, the use of exogenous A T P was suggested for both its G S H 
suppression ability and its selectivity on tumor cells but not on the normal cells 
(Estrela et al, 1995). It was proposed that the growth inhibition of exogenous 
A T P was due to an adenosine-dependent pyrimidine starvation (Weisman et al., 
1988). 
In this chapter, w e studied the growth inhibition effect of exogenous ATP 
- on human hepatoma cells, HepG2, and human normal cell line, the endothelial 
cells ECV304. The effect of exogenous ATP on the antitumor activity of 
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6.2 Materials and Methods 
Cell culture 
HepG2 and ECV304 cells (ATCC) were grown in 75cm2 polystyrene flasks 
(CORNING) in R P M I 1640 (GIBCOBRL) medium, p H 7.4, supplemented with 
10% FCS (GIBCOBRL) and 5% antibiotics (penicillin and streptomycin, 
GIBCOBRL). Cell cultures were maintained in a humidified atmosphere of 5% 
CO2 and at 37^C. O n the day of experiment, cells were removed from the flasks 
with trypsin (GIBCOBRL), containing 0.3mM EDTA, and counted by a 
hemacytometer (Bright-Line). Cells were then plated at a density of 2x104 
cells/well on 96-well plates (CORNING). 
In vitro ATP pretreatment and drug treatment 
A T P (lmM) was freshly prepared every time and diluted to the 
appropriate concentrations by the medium used for cell culture above. Twenty 
four hours after cells being plated, the supernatant was discarded and fresh 
medium containing A T P was added to the cells in 96-well plates. After 24 hours 
incubation in a humidified atmosphere of 5% CO2 and at 370Q the supernatant 
was discarded and fresh medium containing either Doxorubicin (DOX) or 
Mitomycin C (MC) was added. Cells were incubated in the same environment 
for 24 hours before counting. 
« 
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Doxorubicin and Mitomycin C were dissolved in a concentration of l m M 
in distilled water. They were diluted to the appropriate concentrations before use 
by the same cell culture medium above. 
ln vitro cell sampling 
M T T (Sigma) was dissolved (5mg/ml) in ice-cold PBS. The medium was 
discarded and the cells were washed twice with sterile PBS. Then 50^ il M T T 
solution was added to each well. The plates were then incubated for 2 hours at 
370C. Then 150|il D M S O was added to each well and all were incubated for 30 
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6.3 Results 
Effect oflOOuM ATP in 24 hours treatment 
Under an aerobic condition, the doubling time of HepG2 cells was about 
24 hours (Figure 6.3.1). If it was treated with lOO^iM A T P for 24 hours, the 
percentage growth was reduced to only 84% (Figure 6.3.1). The difference of 
percentage growth of ATP-treated HepG2 and that of the untreated was negative 
37.8% (Table 6.3.1), indicating that the percentage cell growth of ATP-treated 
HepG2 was much lower than that of the untreated. The growth of HepG2 cells 
was inhibited by addition of lOO^iM exogenous ATP. O n the other hand, this 
concentration of A T P did not have growth inhibition on ECV304 cells (Figure 
6.3.2) under 24 hours treatment. The difference of percentage growth of ATP-
treated ECV304 and that of the untreated was positive 5.85% (Table 6.3.1), 
indicating that the growth of ECV304 cells was activated by 100^M ATP. Thus, 
the growth inhibition effect of 100^M ATP exerted only on tumor cells but not 
V 
normal cells. 
Effect oflOOuM ATP in 48 hours treatment 
After above 24 hours treatment, HepG2 and ECV304 cells were treated 
with lOO^iM A T P for another 24 hours. The difference of percentage growth of 
ATP-treated HepG2 cells and that of untreated was negative 132.12% (Table 
6.3.1), indicating that repetitive application of lOO^iM ATP would continue to 
% 
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suppress the growth of HepG2 cells and that the effect was much greater than 
that of the first 24-hour treatment (Table 6.3.1). However, there was a little 
growth suppression observed in the normal ECV304 cells (Figure 6.3.2) in this 
treatment. The difference of percentage cell growth of ATP-treated ECV304 cells 
and that of the untreated was negative 85.7% (Table 6.3.1). Comparing with that 
of the HepG2 cells, the growth inhibition effect of the second dose of 100^M A T P 
on normal cells was much lower (Table 6.3.1). 
Effect of200uMATP in 24 hours treatment 
After 24 hours incubation, 200^iM A T P suppressed the growth of HepG2 
cells to 65% cell growth compared to the 122% cell growth of untreated (Figure 
6.3.1). The difference of percentage cell growth of ATP-treated HepG2 to that of 
the untreated was negative 57.8% (Table 6.3.1), suggesting growth inhibition of 
HepG2 was exerted by 200^iM ATP. By comparing to the negative 37.8% under 
100^M A T P treatment, the growth inhibition effect of 200^iM A T P on HepG2 was 
V 
greater than that of the lOO^iM ATP. Under this concentration of ATP, the growth 
of normal ECV304 cells was also inhibited. The percentage cell growth of ATP-
treated ECV304 was 45% and that of the untreated was 51% (Figure 6.3.2). The 
difference of percentage cell growth of ATP-treated ECV304 and that of the 
untreated was negative 6.39% (Table 6.3.1), and that of ATP-treated HepG2 was 
negative 57.8% (Table 6.3.1). This showed that the growth inhibition effect of 
200^iM A T P on HepG2 was much greater than that on ECV304. This implied that 
» 
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the growth inhibition effect of exogenous A T P on tumor cells was much greater 
than that on normal cells. 
Effect of200uM ATP in 48 hours treatment 
After 24 hours treatment, HepG2 and ECV304 cells were treated with 
200^iM A T P for another 24 hours. The difference of percentage cell growth of 
ATP-treated and that of untreated was negative 169.3% and that of the first 24-
hour A T P treatment was 57.8% (Table 6.3.1). This indicated that repetitive dose 
of A T P continued to exert its growth inhibition effect and such effect after second 
24-hour treatment was much greater than that of the first 24-hour treatment. The 
difference of percentage cell growth of ATP-treated ECV304 and that of the 
untreated was negative 78% and that of the first 24-hour treatment was negative 
6.39% (Table 6.3.1). The growth inhibition effect after the second 24-hour 
treatment was much greater than that of the first 24-hour treatment. Comparing 
to that of the ATP-treated HepG2, the growth inhibition effect of A T P on ECV304 
y 
after the second 24-hour treatment was much lower (Table 6.3.1). The growth 
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Figure 6.3.1 Effect of exogenous A T P on the growth of HepG2 cells. 
HepG2 cells (2x10^ per well) were seeded onto 96-well plates. After 24 hours, 
ATP was dissolved in RPMI (with 10% FCS and 5% antibiotics) and added to the 
cells. After 24 hours, the supeynatant was discarded and the same treatment of 
A T P was repeated. At each 24-hour interval, the viability of cells was measured 
by M T T Assay. After discarding the medium, M T T solution (5mg/ml in PBS) 
was added 50^ il per well for a 2-hour incubation. Then 150^ il D M S O was added 
per well for a 0.5 hour incubation and O.D.s40 was taken. 
秦 
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Figure 6.3.2 Effect of exogenous A T P on the growth of ECV304 cells. 
ECV304 cells (2x10^ per well) were seeded onto 96-well plates. After 24 hours, 
A T P was dissolved in RPMI (with 10% FCS and 5% antibiotics) and added to the 
cells. After 24 hours, the supernatant was discarded and the same treatment of 
A T P was repeated. At each 24-hour interval, the viability of cells was measured 
by M T T Assay. After discarding the medium, M T T solution (5mg/mI in PBS) 
was added 50^ il per well for a 2-hour incubation. Then 150^ il D M S O was added 




Effect ofexogenous ATP on DOX- orMC-treated HepG2 
Concentration 
Cell lines of ATP (^ iM) Treatment duration 
24 hr. 48 hr. 
HepG2 100 -37.80% -132.12% 
ECV304 100 5.85% -85.70% 
HepG2 200 -57.80% -169.30% 
ECV304 200 -6.39% -78.01% 
Table 6.3.1 Differences of Average Percentage Cell Viability between 
ATP-treated and untreated cells. Each cell line was 
compared with its own control. 
The value of differences of Average Percentage Cell Viability was obtained by 
comparing the “ Average Percentage Cell Viability “ of ATP-treated cells with 
that of the respective untreated cells. Negative value implies that the growth of 
the ATP-treated cells was inhibited and the Percentage Cell Viability of the ATP-
treated cells was less than that of the untreated cells. O n the other hand, positive 
value implied that the growth of ATP-treated cells was activated and the 
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Effect ofATP treatment on the cytotoxicity ofDOX on HevG2 
After a 24-hour pretreatment of exogenous ATP, w e found that the 
cytotoxic effect of Doxorubicin (DOX) on HepG2 cells was enhanced (Figure 
6.3.3). The IC50 of D O X on HepG2 without pretreatment of A T P was about 5^iM. 
If HepG2 was pretreated with lOO^iM A T P for 24 hours, the IC50 of D O X dropped 
to 4 ^ M whilst it dropped to 0.625^iM if HepG2 was pretreated with 200^iM A T P 
for 24 hours as well (Figure 6.3.3). 
At lower concentrations of D O X , e.g. concentrations less than 5^iM, the 
effect of 200^iM A T P on the enhancement of D O X cytotoxicity was obvious and 
much greater than that of lOO^iM ATP (Figure 6.3.3). 
At high concentrations of D O X , e.g. concentrations greater than 5^iM, the 
effect of lOOjxM A T P on the enhancement of D O X cytotoxicity was nearly the 
same as that of 200^iM A T P (Figure 6.3.3). 
For concentrations of D O X greater than 5^iM, lOOfiM A T P and 200^M ATP 
showed an average of 13% and 14% cytotoxicity enhancement respectively 
»K-
(Figure 6.3.3). 
In conclusion, pretreatment of lOO^iM or 200^iM ATP for 24 hours did 
enhance the cytotoxicity of D O X on HepG2 cells for concentrations of D O X used 
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Figure 6.3.3 Effect of exogenous ATP treatment on the antitumor 
activity of Doxorubicin (DOX) on HepG2 cells. 
HepG2 cells (2x10^ per well) were seeded onto 96-well plates. After 24 hours, 
A T P was dissolved in RPMI (with 10% FCS and 5% antibiotics) and added to the 
cells. After 24 hours, the supernatant was discarded and fresh medium 
containing Doxorubicin was added for another 24 hours incubation. The viability 
of cells was measured by M T T Assay. After discarding the medium, M T T 
solution (5mg/ml in PBS) was added 50^1 per well for a 2-hour incubation. Then 
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Effect ofATP treatment on the cvtotoxicitu ofMC on HepG2 
After a 24-hour pretreatment of exogenous ATP, w e found that the 
cytotoxic effect of Mitomycin C (MC) on HepG2 cells was enhanced (Figure 
6.3,4). The IC50 of M C on HepG2 without pretreatment of A T P was about 19^M. 
After pretreatment of lOO^iM A T P for 24 hours, the IC50 of M C on HepG2 
dropped to 7[iM (Figure 6.3.4). O n the other hand, the IC50 of M C dropped to 
3.5^iM if the cells were pretreated with 200^iM A T P for 24 hours (Figure 6.3.4). 
For concentrations of M C used in this experiment, 100^M and 200^iM A T P 
showed very great enhancement of the cytotoxicity of M C on HepG2 cells. The 
difference between the effect of lOO^iM and 200^iM A T P was not big and obvious 
(Figure 6.3.4). 
The two concentrations of ATP, 100^M and 200^iM, showed an average of 
27% and 30% cytotoxicity enhancement (Figure 6.3.4) respectively. In conclusion, 
pretreatment of either lOO^iM ATP or 200^iM ATP enhanced the cytotoxicity of 
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Figure 6.3.4 Effect of exogenous ATP treatment on the antitumor 
activity of Mitomycin C (MC) on HepG2 cells. 
HepG2 cells (2x10^ per well) were seeded onto 96-well plates. After 24 hours, 
‘ ATP was dissolved in RPMI (with 10% FCS and 5% antibiotics) and added to the 
cells. After 24 hours, the supernatant was discarded and fresh medium 
containing Mitomycin C was added for another 24 hours incubation. The 
viability of cells was measured by M T T Assay. After discarding the medium, 
M T T solution (5mg/ml in PBS) was added 50fil per well for a 2-hour incubation. 
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6.4 Discussion 
In cancer chemotherapy, the adverse side effects of antineoplastic drugs 
on the normal tissues limit the dose, especially on the cumulative dose of the 
drugs that can be given to the patients. In lower drug dosage, the rapid growth 
of the tumor tissues make them difficult to be completely erased. These problems 
raise the interest of experiments to search for specific treatments that can 
selectively discriminate normal tissues from tumor tissues, and suppress the 
proliferation of tumor tissues rather than normal tissues. In such way, the 
optimal dose of antineoplastic drugs can be lowered but their effectiveness can 
still be retained. 
It was reported that extracellular adenosine can suppress the growth of 
transformed fibroblasts and such growth inhibition is due to adenosine 
generated slowly from the nucleotides by enzymes on the cell surface and in 
serum causing an adenosine-dependent pyrimidine starvation intracellularly 
(Weisman et al, 1988). In our m vitro study, either 100^M or 200^iM exogenous 
A T P was found to highly suppress the growth of human hepatoma cells, HepG2. 
Repetitive treatment of both these two concentrations of A T P showed much 
greater growth inhibition effect on HepG2 cells. W e suggested that repeat 
administration of exogenous ATP could somehow suppress the proliferation of 
human cancer cells. However, w e found that lOO^iM ATP slightly activated the 
growth of normal cell line, ECV304, compared with that of the cancer cell line 
« 
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(Table 6.3.1). Though there was growth inhibition in normal cell line in either 
repetitive treatment or higher concentration of A T P (Table 6.3.1), this effect on 
normal cell line was much lower than that on tumor cell line. 
In fact, most of the normal tissues are terminally differentiated or they 
have a very slow proliferation rate. W e suggested that the growth inhibition 
effect of exogenous A T P on normal tissues should be much less than that in 
cancer cells. O n the other hand, as the growth suppression of exogenous A T P is 
very high on tumor cells, w e suggested that A T P treatment could be used as a 
selective means to separate tumor cells from normal cells. Also by such effect, the 
tumor tissues became more susceptible to the cytotoxicity of the antineoplastic 
drugs. Thus lower drug dosage might have the same effect of that of high 
dosage. 
W e found that if HepG2 cells were pretreated with either lOO^iM ATP or 
200^iM ATP, the cytotoxicity of Doxorubicin (DOX) and Mitomycin C (MC) on 
HepG2 cells were greatly enhanced (Figure 6.3.3 and 6.3.4). The amount of D O X 
or M C required to give 50% cytotoxicity on HepG2 cells was reduced in ATP-
pretreated HepG2. This effect was much greater if the HepG2 was pretreated 
with 200^iM ATP compared to that of lOO^iM ATP. Nevertheless, w e found that 
exogenous A T P did enhance the antitumor activity of antineoplastic drugs on 
tumor cells by increasing their sensitivity and making them more susceptible to 
the cytotoxicity of these drugs. 
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The mechanism of such effect of exogenous A T P is not known yet. 
Previously, it was reported that elevation of intracellular reduced glutathione 
(GSH) was associated with mitogenic stimulation (Shaw and Chou, 1986), that 
G S H might regulate D N A synthesis (Suthanthiran et al, 1990), that G S H 
regulated the onset of tumor-cell proliferation by modulating protein kinase C 
activity and intracellular p H (Terradez et al, 1993) and that G S H content 
decreased during tumor growth in vivo when cell proliferation and the rate of 
protein synthesis in the tumor decreased (Estrela et al., 1992). Therefore, changes 
in the rate of cancer cell proliferation might be reflected by changes in their 
intracellular G S H levels. In fact, it was found that extracellular A T P inhibited 
cancer growth and selectively depleted glutathione levels in cancer cells (Lasso 
De La Vega et al., 1994). In view of this, w e suggested that exogenous A T P might 
weaken the intracellular defence system of HepG2 cells by lowering the 
intracellular G S H levels in HepG2, making them more susceptible to the 
cytotoxic effect of D O X and M C in our experiments. To confirm this possibility, 
V-
more experiments are required. 
As the use of exogenous ATP was extended to the elimination of tumor 
cells by the combination of ATP and X-rays (Estrela et al., 1995) in vivo, w e 
suggest that in future the combination of ATP and common antineoplastic drugs, 
such as Doxorubicin and Mitomycin C, should be tested to examine whether 
tumor cells can more effectively be erased in mouse model or even in clinical 
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CHAPTER SEVEN 
7.1 Conclusion 
In this research, w e have demonstrated that the two antioxidants, (+)-
Catechin (CAT) and N-Propyl gallate (NPG) showed antiproliferative effect on 
human hepatoma cell line, HepG2, and enhancement the cytotoxic effect of 
Doxorubicin (DOX) and Mitomycin C (MC) on HepG2 in vitro under aerobic 
condition. N P G was capable of protecting human normal endothelial cell line, 
ECV304, against the cytotoxic effects of D O X or M C , which are known to be 
mediated by free radicals, by increasing the expression of antioxidant enzyme 
M n - S O D R N A in vitro. Such induction was very low in hepatoma cell line, 
HepG2 that N P G would not protect HepG2 from cytotoxicity of D O X and M C . 
This finding may imply that N P G can be used to protect normal cells when D O X 
or M C is applied to kill the cancer cells clinically with the benefit of enhancement 
of antitumor activity of D O X or M C . 
Similar resutls were found in EAT-bearing mice study, both D O X and M C 
showed great antitumor activity in vivo. C A T enhanced the antitumor effect of 
D O X , whilst N P G enhanced the antitumor effect of M C . W e also found that N P G 
and C A T when applied concomitantly with D O X or M C to kill E A T cells in vivo, 
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antitumor effect of both N P G and C A T and their antioxidant effect against the 
free radical-mediated adverse side effects of D O X and M C . 
By observing the histological section of hearts of EAT-bearing mice, w e 
found disruption of myocardial filament and presence of vacuolisation after 
D O X treatment. This damage could be restored by co-treatment of N P G and with 
D O X . O n the other hand, although D O X or M C cause significant lipid 
peroxidation in hearts of EAT-bearing mice comparing to control, w e could not 
observe that N P G could reduce this lipid peroxidation effect of M C This may be 
due to the limitation of thiobarbituric acid (TBA) assay of lipid peroxidation. It is 
believed that mitochondria are the most susceptible site for the free radical attack 
mediated by D O X (Olson and Mushlin, 1990). Thus lipid peroxidation may not 
be intensive enough for the T B A measurement. 
In the Langendorff isolated perfused rat heart model, w e demonstrated 
that D O X and M C exhibited cardiotoxic effects by reducing the cardiac 
performance ex vivo. Both D O X and M C lowered the Contraction Force, Heart 
Beat Rate and Flow Rate bf perfusate. By perfusing with (+)-Catechin 
simultaneously with D O X or M C , w e observed that (+)-Catechin protected the 
isolated rat heart from the free radical attack of D O X and M C by recovering the 
cardiac performance of the rat hearts. 
Moreover, w e found that exogenous ATP could suppress the proliferation 
of human hepatoma cell, HepG2, but not human normal umbilical cord 
endothelial cell line, ECV304. Such effect may be due to an intracellular 
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adenosine-dependent starvation effect caused by continuous extracellular 
generation of adenosine from exogenous A T P (Weisman et al., 1988). W e also 
observed that pre-treatment of HepG2 with exogenous A T P made it more 
sensitive and susceptible to the cytotoxicity of D O X and M C in vitro. Thus the 
antitumor activity of D O X or M C could be enhanced by exogenous ATP. This 
effect m a y be due to the intracellular glutathione (GSH) depletion activity of 
exogenous A T P that the defence system of tumor cells was weakened. 
7.2 Future prospects 
Though the antitumor and antiproliferative effects of naturally occurring 
polyphenolic compounds are still controversial, their antioxidant effects are well-
documented in vitro and in vivo (Kuo, 1997). As the side effects of antitumor 
drugs greatly lower their optimal dose in cancer chemotherapy, a potential 
application is the possible synergism of antioxidants with chemotherapeutic 
agents so as to lower the side effects of common antitumor drugs without 
lowering their antitumor effects. The question lies on the absorption rate and 
bioavailability of these antioxidants in human. Co-treatment of antioxidants with 
antitumor drugs can be an alternative. It is suggested that the antioxidants can be 
even given to patient prior to chemotherapy and also at the same time of 
chemotherapy so that the patients are well-equipped with antioxidants so as to 
minimise the toxic effect of antitumor drugs. Moreover, antioxidants possessing 
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antiproliferative effect can be applied with antitumor drugs so that less 
antitumor drugs can be used to obtain the same antitumor effect but lower the 
adverse side effects of the drugs. In this aspect, the application of (+)-Catechin 
and N-Propyl gallate is of special interest. They are non-toxic to normal cells. (+)-
Catechin is contained in green tea extract and N-Propyl gallate has been used in 
food supplement. They can safely be used in cancer patients to counteract the 
cardiotoxic adverse effect of Doxorubicin and/or Mitomycin C during 
chemotherapy. 
Although promising data have been provided in this thesis, further 
research, e.g. optimal dosage and administration protocol, is needed before these 
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